id	sid	tid	token	lemma	pos
njb-229	1	1	nepal	nepal	PROPN
njb-229	1	2	j	j	PROPN
njb-229	1	3	biotechnol	biotechnol	PROPN
njb-229	1	4	.	.	PUNCT
njb-229	2	1	2	2	NUM
njb-229	2	2	0	0	NUM
njb-229	2	3	2	2	NUM
njb-229	2	4	2	2	NUM
njb-229	2	5	j	j	NOUN
njb-229	2	6	u	u	NOUN
njb-229	2	7	l	l	NOUN
njb-229	2	8	;	;	PUNCT
njb-229	2	9	1	1	NUM
njb-229	2	10	0	0	NUM
njb-229	2	11	(	(	PUNCT
njb-229	2	12	1	1	NUM
njb-229	2	13	):	):	PUNCT
njb-229	2	14	4	4	NUM
njb-229	2	15	0	0	NUM
njb-229	2	16	4	4	NUM
njb-229	2	17	4	4	NUM
njb-229	2	18	research	research	NOUN
njb-229	2	19	article	article	NOUN
njb-229	2	20	doi	doi	X
njb-229	2	21	:	:	PUNCT
njb-229	2	22	https://doi.org/10.54796/njb.v10i1.229	https://doi.org/10.54796/njb.v10i1.229	PROPN
njb-229	2	23	©	©	PROPN
njb-229	2	24	njb	njb	PROPN
njb-229	2	25	,	,	PUNCT
njb-229	2	26	bsn	bsn	PROPN
njb-229	2	27	40	40	NUM
njb-229	2	28	screening	screening	NOUN
njb-229	2	29	of	of	ADP
njb-229	2	30	carbapenem	carbapenem	PROPN
njb-229	2	31	resistance	resistance	PROPN
njb-229	2	32	klebsiella	klebsiella	PROPN
njb-229	2	33	pneumoniae	pneumoniae	PROPN
njb-229	2	34	and	and	CCONJ
njb-229	2	35	its	its	PRON
njb-229	2	36	mic	mic	NOUN
njb-229	2	37	against	against	ADP
njb-229	2	38	imipenem	imipenem	PROPN
njb-229	2	39	sarada	sarada	PROPN
njb-229	2	40	saud1	saud1	PROPN
njb-229	2	41	,	,	PUNCT
njb-229	2	42	ashwani	ashwani	PROPN
njb-229	2	43	agrawal1	agrawal1	PROPN
njb-229	2	44	,	,	PUNCT
njb-229	2	45	soniya	soniya	PROPN
njb-229	2	46	pokhrel1	pokhrel1	PROPN
njb-229	2	47	,	,	PUNCT
njb-229	2	48	sushma	sushma	PROPN
njb-229	2	49	subedi1	subedi1	PROPN
njb-229	2	50	,	,	PUNCT
njb-229	2	51	sanjit	sanjit	PROPN
njb-229	2	52	shrestha2	shrestha2	PROPN
njb-229	2	53	,	,	PUNCT
njb-229	2	54	and	and	CCONJ
njb-229	2	55	niroj	niroj	PROPN
njb-229	2	56	man	man	PROPN
njb-229	2	57	amatya	amatya	PROPN
njb-229	2	58	1	1	PROPN
njb-229	2	59	1department	1department	NUM
njb-229	2	60	of	of	ADP
njb-229	2	61	medical	medical	ADJ
njb-229	2	62	microbiology	microbiology	NOUN
njb-229	2	63	,	,	PUNCT
njb-229	2	64	nobel	nobel	PROPN
njb-229	2	65	college	college	PROPN
njb-229	2	66	,	,	PUNCT
njb-229	2	67	sinamangal	sinamangal	ADJ
njb-229	2	68	,	,	PUNCT
njb-229	2	69	kathmandu	kathmandu	NOUN
njb-229	2	70	,	,	PUNCT
njb-229	2	71	nepal	nepal	ADJ
njb-229	2	72	affiliated	affiliate	VERB
njb-229	2	73	to	to	ADP
njb-229	2	74	pokhara	pokhara	PROPN
njb-229	2	75	university	university	PROPN
njb-229	2	76	.	.	PUNCT
njb-229	3	1	2pathology	2pathology	NUM
njb-229	3	2	department	department	NOUN
njb-229	3	3	,	,	PUNCT
njb-229	3	4	b	b	PROPN
njb-229	3	5	&	&	CCONJ
njb-229	3	6	b	b	PROPN
njb-229	3	7	hospital	hospital	PROPN
njb-229	3	8	,	,	PUNCT
njb-229	3	9	lalitpur	lalitpur	PROPN
njb-229	3	10	,	,	PUNCT
njb-229	3	11	nepal	nepal	ADJ
njb-229	3	12	.	.	PUNCT
njb-229	4	1	received	receive	VERB
njb-229	4	2	:	:	PUNCT
njb-229	4	3	26	26	NUM
njb-229	4	4	feb	feb	PROPN
njb-229	4	5	2022	2022	NUM
njb-229	4	6	;	;	PUNCT
njb-229	4	7	revised	revise	VERB
njb-229	4	8	:	:	PUNCT
njb-229	4	9	20	20	NUM
njb-229	4	10	jul	jul	PROPN
njb-229	4	11	2022	2022	NUM
njb-229	4	12	;	;	PUNCT
njb-229	4	13	accepted	accept	VERB
njb-229	4	14	:	:	PUNCT
njb-229	4	15	26	26	NUM
njb-229	4	16	jul	jul	PROPN
njb-229	4	17	2022	2022	NUM
njb-229	4	18	;	;	PUNCT
njb-229	4	19	published	publish	VERB
njb-229	4	20	online	online	ADV
njb-229	4	21	:	:	PUNCT
njb-229	4	22	30	30	NUM
njb-229	4	23	jul	jul	PROPN
njb-229	4	24	2022	2022	NUM
njb-229	4	25	abstract	abstract	ADJ
njb-229	4	26	klebsiella	klebsiella	PROPN
njb-229	4	27	pneumoniae	pneumoniae	NOUN
njb-229	4	28	is	be	AUX
njb-229	4	29	a	a	DET
njb-229	4	30	common	common	ADJ
njb-229	4	31	opportunistic	opportunistic	ADJ
njb-229	4	32	pathogen	pathogen	NOUN
njb-229	4	33	causing	cause	VERB
njb-229	4	34	a	a	DET
njb-229	4	35	wide	wide	ADJ
njb-229	4	36	range	range	NOUN
njb-229	4	37	of	of	ADP
njb-229	4	38	infections	infection	NOUN
njb-229	4	39	;	;	PUNCT
njb-229	4	40	pneumonia	pneumonia	NOUN
njb-229	4	41	,	,	PUNCT
njb-229	4	42	urinary	urinary	ADJ
njb-229	4	43	tract	tract	NOUN
njb-229	4	44	infection	infection	NOUN
njb-229	4	45	,	,	PUNCT
njb-229	4	46	bacteremia	bacteremia	NOUN
njb-229	4	47	,	,	PUNCT
njb-229	4	48	and	and	CCONJ
njb-229	4	49	liver	liver	NOUN
njb-229	4	50	abscesses	abscess	NOUN
njb-229	4	51	.	.	PUNCT
njb-229	5	1	it	it	PRON
njb-229	5	2	infects	infect	VERB
njb-229	5	3	primarily	primarily	ADV
njb-229	5	4	immunocompromised	immunocompromise	VERB
njb-229	5	5	and	and	CCONJ
njb-229	5	6	immunocompetent	immunocompetent	ADJ
njb-229	5	7	individuals	individual	NOUN
njb-229	5	8	.	.	PUNCT
njb-229	6	1	it	it	PRON
njb-229	6	2	presents	present	VERB
njb-229	6	3	itself	itself	PRON
njb-229	6	4	as	as	ADP
njb-229	6	5	an	an	DET
njb-229	6	6	antibiotic	antibiotic	ADJ
njb-229	6	7	-	-	PUNCT
njb-229	6	8	resistant	resistant	ADJ
njb-229	6	9	bacterium	bacterium	NOUN
njb-229	6	10	,	,	PUNCT
njb-229	6	11	especially	especially	ADV
njb-229	6	12	for	for	ADP
njb-229	6	13	third	third	ADJ
njb-229	6	14	-	-	PUNCT
njb-229	6	15	generation	generation	NOUN
njb-229	6	16	cephalosporins	cephalosporin	NOUN
njb-229	6	17	and	and	CCONJ
njb-229	6	18	carbapenems	carbapenem	NOUN
njb-229	6	19	,	,	PUNCT
njb-229	6	20	creating	create	VERB
njb-229	6	21	serious	serious	ADJ
njb-229	6	22	global	global	ADJ
njb-229	6	23	challenges	challenge	NOUN
njb-229	6	24	.	.	PUNCT
njb-229	7	1	therefore	therefore	ADV
njb-229	7	2	,	,	PUNCT
njb-229	7	3	this	this	DET
njb-229	7	4	cross	cross	ADJ
njb-229	7	5	-	-	ADJ
njb-229	7	6	sectional	sectional	ADJ
njb-229	7	7	study	study	NOUN
njb-229	7	8	was	be	AUX
njb-229	7	9	conducted	conduct	VERB
njb-229	7	10	in	in	ADP
njb-229	7	11	b	b	PROPN
njb-229	7	12	&	&	CCONJ
njb-229	7	13	b	b	PROPN
njb-229	7	14	hospital	hospital	PROPN
njb-229	7	15	,	,	PUNCT
njb-229	7	16	lalitpur	lalitpur	PROPN
njb-229	7	17	to	to	PART
njb-229	7	18	screen	screen	VERB
njb-229	7	19	the	the	DET
njb-229	7	20	distribution	distribution	NOUN
njb-229	7	21	of	of	ADP
njb-229	7	22	carbapenem	carbapenem	PROPN
njb-229	7	23	resistance	resistance	NOUN
njb-229	7	24	k.	k.	PROPN
njb-229	7	25	pneumoniae	pneumoniae	NOUN
njb-229	7	26	through	through	ADP
njb-229	7	27	ertapenem	ertapenem	PROPN
njb-229	7	28	and	and	CCONJ
njb-229	7	29	to	to	PART
njb-229	7	30	assess	assess	VERB
njb-229	7	31	the	the	DET
njb-229	7	32	minimum	minimum	ADJ
njb-229	7	33	inhibitory	inhibitory	ADJ
njb-229	7	34	concentration	concentration	NOUN
njb-229	7	35	of	of	ADP
njb-229	7	36	imipenem	imipenem	PROPN
njb-229	7	37	for	for	ADP
njb-229	7	38	screened	screen	VERB
njb-229	7	39	carbapenem	carbapenem	PROPN
njb-229	7	40	resistance	resistance	NOUN
njb-229	7	41	k.	k.	PROPN
njb-229	7	42	pneumoniae	pneumoniae	NOUN
njb-229	7	43	.	.	PUNCT
njb-229	8	1	from	from	ADP
njb-229	8	2	3447	3447	NUM
njb-229	8	3	different	different	ADJ
njb-229	8	4	clinical	clinical	ADJ
njb-229	8	5	samples	sample	NOUN
njb-229	8	6	collected	collect	VERB
njb-229	8	7	according	accord	VERB
njb-229	8	8	to	to	ADP
njb-229	8	9	standard	standard	ADJ
njb-229	8	10	guidelines	guideline	NOUN
njb-229	8	11	,	,	PUNCT
njb-229	8	12	k.	k.	NOUN
njb-229	8	13	pneumoniae	pneumoniae	NOUN
njb-229	8	14	was	be	AUX
njb-229	8	15	identified	identify	VERB
njb-229	8	16	using	use	VERB
njb-229	8	17	standard	standard	ADJ
njb-229	8	18	microbiological	microbiological	ADJ
njb-229	8	19	techniques	technique	NOUN
njb-229	8	20	;	;	PUNCT
njb-229	8	21	staining	staining	NOUN
njb-229	8	22	and	and	CCONJ
njb-229	8	23	a	a	DET
njb-229	8	24	panel	panel	NOUN
njb-229	8	25	of	of	ADP
njb-229	8	26	biochemical	biochemical	ADJ
njb-229	8	27	tests	test	NOUN
njb-229	8	28	.	.	PUNCT
njb-229	9	1	the	the	DET
njb-229	9	2	antibiotic	antibiotic	ADJ
njb-229	9	3	susceptibility	susceptibility	NOUN
njb-229	9	4	test	test	NOUN
njb-229	9	5	of	of	ADP
njb-229	9	6	the	the	DET
njb-229	9	7	isolates	isolate	NOUN
njb-229	9	8	was	be	AUX
njb-229	9	9	performed	perform	VERB
njb-229	9	10	by	by	ADP
njb-229	9	11	the	the	DET
njb-229	9	12	kirby	kirby	PROPN
njb-229	9	13	-	-	PUNCT
njb-229	9	14	bauer	bauer	NOUN
njb-229	9	15	disc	disc	NOUN
njb-229	9	16	diffusion	diffusion	NOUN
njb-229	9	17	method	method	NOUN
njb-229	9	18	as	as	ADP
njb-229	9	19	per	per	ADP
njb-229	9	20	clsi	clsi	NOUN
njb-229	9	21	2018	2018	NUM
njb-229	9	22	guidelines	guideline	NOUN
njb-229	9	23	.	.	PUNCT
njb-229	10	1	the	the	DET
njb-229	10	2	screening	screening	NOUN
njb-229	10	3	of	of	ADP
njb-229	10	4	carbapenem	carbapenem	PROPN
njb-229	10	5	resistance	resistance	NOUN
njb-229	10	6	was	be	AUX
njb-229	10	7	assessed	assess	VERB
njb-229	10	8	by	by	ADP
njb-229	10	9	using	use	VERB
njb-229	10	10	ertapenem	ertapenem	PROPN
njb-229	10	11	disc	disc	NOUN
njb-229	10	12	and	and	CCONJ
njb-229	10	13	the	the	DET
njb-229	10	14	mic	mic	NOUN
njb-229	10	15	of	of	ADP
njb-229	10	16	imipenem	imipenem	PROPN
njb-229	10	17	for	for	ADP
njb-229	10	18	carbapenem	carbapenem	PROPN
njb-229	10	19	resistance	resistance	NOUN
njb-229	10	20	and	and	CCONJ
njb-229	10	21	intermediate	intermediate	ADJ
njb-229	10	22	was	be	AUX
njb-229	10	23	performed	perform	VERB
njb-229	10	24	using	use	VERB
njb-229	10	25	an	an	DET
njb-229	10	26	epsilometer	epsilometer	NOUN
njb-229	10	27	.	.	PUNCT
njb-229	11	1	a	a	DET
njb-229	11	2	total	total	NOUN
njb-229	11	3	of	of	ADP
njb-229	11	4	85	85	NUM
njb-229	11	5	k.	k.	NOUN
njb-229	11	6	pneumoniae	pneumoniae	NOUN
njb-229	11	7	were	be	AUX
njb-229	11	8	identified	identify	VERB
njb-229	11	9	and	and	CCONJ
njb-229	11	10	their	their	PRON
njb-229	11	11	antibiotic	antibiotic	ADJ
njb-229	11	12	susceptibility	susceptibility	NOUN
njb-229	11	13	test	test	NOUN
njb-229	11	14	revealed	reveal	VERB
njb-229	11	15	that	that	SCONJ
njb-229	11	16	ceftriaxone	ceftriaxone	PROPN
njb-229	11	17	was	be	AUX
njb-229	11	18	the	the	DET
njb-229	11	19	least	least	ADJ
njb-229	11	20	effective	effective	ADJ
njb-229	11	21	antibiotic	antibiotic	NOUN
njb-229	11	22	.	.	PUNCT
njb-229	12	1	the	the	DET
njb-229	12	2	number	number	NOUN
njb-229	12	3	of	of	ADP
njb-229	12	4	mdr	mdr	PROPN
njb-229	12	5	,	,	PUNCT
njb-229	12	6	carbapenem	carbapenem	PROPN
njb-229	12	7	-	-	PUNCT
njb-229	12	8	resistant	resistant	ADJ
njb-229	12	9	and	and	CCONJ
njb-229	12	10	intermediate	intermediate	ADJ
njb-229	12	11	isolates	isolate	NOUN
njb-229	12	12	was	be	AUX
njb-229	12	13	51	51	NUM
njb-229	12	14	,	,	PUNCT
njb-229	12	15	46	46	NUM
njb-229	12	16	,	,	PUNCT
njb-229	12	17	and	and	CCONJ
njb-229	12	18	3	3	NUM
njb-229	12	19	,	,	PUNCT
njb-229	12	20	respectively	respectively	ADV
njb-229	12	21	.	.	PUNCT
njb-229	13	1	the	the	DET
njb-229	13	2	mic	mic	NOUN
njb-229	13	3	of	of	ADP
njb-229	13	4	imipenem	imipenem	PROPN
njb-229	13	5	through	through	ADP
njb-229	13	6	an	an	DET
njb-229	13	7	epsilometer	epsilometer	NOUN
njb-229	13	8	from	from	ADP
njb-229	13	9	ertapenem	ertapenem	PROPN
njb-229	13	10	resistant	resistant	ADJ
njb-229	13	11	and	and	CCONJ
njb-229	13	12	intermediate	intermediate	ADJ
njb-229	13	13	revealed	reveal	VERB
njb-229	13	14	that	that	SCONJ
njb-229	13	15	31	31	NUM
njb-229	13	16	,	,	PUNCT
njb-229	13	17	5	5	NUM
njb-229	13	18	,	,	PUNCT
njb-229	13	19	and	and	CCONJ
njb-229	13	20	13	13	NUM
njb-229	13	21	isolates	isolate	NOUN
njb-229	13	22	were	be	AUX
njb-229	13	23	resistant	resistant	ADJ
njb-229	13	24	,	,	PUNCT
njb-229	13	25	intermediate	intermediate	ADJ
njb-229	13	26	,	,	PUNCT
njb-229	13	27	and	and	CCONJ
njb-229	13	28	sensitive	sensitive	ADJ
njb-229	13	29	respectively	respectively	ADV
njb-229	13	30	.	.	PUNCT
njb-229	14	1	these	these	DET
njb-229	14	2	findings	finding	NOUN
njb-229	14	3	showed	show	VERB
njb-229	14	4	the	the	DET
njb-229	14	5	inconsistency	inconsistency	NOUN
njb-229	14	6	in	in	ADP
njb-229	14	7	the	the	DET
njb-229	14	8	detection	detection	NOUN
njb-229	14	9	of	of	ADP
njb-229	14	10	carbapenem	carbapenem	NOUN
njb-229	14	11	-	-	PUNCT
njb-229	14	12	resistant	resistant	ADJ
njb-229	14	13	isolates	isolate	NOUN
njb-229	14	14	in	in	ADP
njb-229	14	15	routine	routine	ADJ
njb-229	14	16	microbiology	microbiology	NOUN
njb-229	14	17	laboratories	laboratory	NOUN
njb-229	14	18	and	and	CCONJ
njb-229	14	19	further	far	ADV
njb-229	14	20	support	support	VERB
njb-229	14	21	the	the	DET
njb-229	14	22	other	other	ADJ
njb-229	14	23	tests	test	NOUN
njb-229	14	24	for	for	ADP
njb-229	14	25	the	the	DET
njb-229	14	26	detection	detection	NOUN
njb-229	14	27	of	of	ADP
njb-229	14	28	carbapenem	carbapenem	PROPN
njb-229	14	29	resistance	resistance	NOUN
njb-229	14	30	as	as	SCONJ
njb-229	14	31	suggested	suggest	VERB
njb-229	14	32	by	by	ADP
njb-229	14	33	clsi	clsi	NOUN
njb-229	14	34	.	.	PUNCT
njb-229	15	1	keywords	keyword	NOUN
njb-229	15	2	:	:	PUNCT
njb-229	15	3	carbapenem	carbapenem	PROPN
njb-229	15	4	-	-	PUNCT
njb-229	15	5	resistant	resistant	ADJ
njb-229	15	6	klebsiella	klebsiella	PROPN
njb-229	15	7	pneumoniae	pneumoniae	PROPN
njb-229	15	8	,	,	PUNCT
njb-229	15	9	ertapenem	ertapenem	PROPN
njb-229	15	10	,	,	PUNCT
njb-229	15	11	mic	mic	ADJ
njb-229	15	12	corresponding	correspond	VERB
njb-229	15	13	author	author	NOUN
njb-229	15	14	,	,	PUNCT
njb-229	15	15	e	e	NOUN
njb-229	15	16	-	-	NOUN
njb-229	15	17	mail	mail	NOUN
njb-229	15	18	:	:	PUNCT
njb-229	15	19	mahaju@gmail.com	mahaju@gmail.com	X
njb-229	15	20	introduction	introduction	NOUN
njb-229	15	21	klebsiella	klebsiella	PROPN
njb-229	15	22	pneumoniae	pneumoniae	NOUN
njb-229	15	23	,	,	PUNCT
njb-229	15	24	an	an	DET
njb-229	15	25	important	important	ADJ
njb-229	15	26	member	member	NOUN
njb-229	15	27	of	of	ADP
njb-229	15	28	the	the	DET
njb-229	15	29	enterobacteriaceae	enterobacteriaceae	PROPN
njb-229	15	30	family	family	NOUN
njb-229	15	31	;	;	PUNCT
njb-229	15	32	residing	reside	VERB
njb-229	15	33	in	in	ADP
njb-229	15	34	the	the	DET
njb-229	15	35	gastrointestinal	gastrointestinal	ADJ
njb-229	15	36	tract	tract	NOUN
njb-229	15	37	of	of	ADP
njb-229	15	38	us	we	PRON
njb-229	15	39	,	,	PUNCT
njb-229	15	40	is	be	AUX
njb-229	15	41	not	not	PART
njb-229	15	42	only	only	ADV
njb-229	15	43	the	the	DET
njb-229	15	44	most	most	ADV
njb-229	15	45	clinically	clinically	ADV
njb-229	15	46	isolated	isolate	VERB
njb-229	15	47	opportunistic	opportunistic	ADJ
njb-229	15	48	pathogen	pathogen	NOUN
njb-229	15	49	from	from	ADP
njb-229	15	50	immunecompromised	immunecompromise	VERB
njb-229	15	51	individuals	individual	NOUN
njb-229	15	52	,	,	PUNCT
njb-229	15	53	neonates	neonate	NOUN
njb-229	15	54	,	,	PUNCT
njb-229	15	55	critically	critically	ADV
njb-229	15	56	ill	ill	ADJ
njb-229	15	57	patients	patient	NOUN
njb-229	15	58	,	,	PUNCT
njb-229	15	59	or	or	CCONJ
njb-229	15	60	patients	patient	NOUN
njb-229	15	61	with	with	ADP
njb-229	15	62	other	other	ADJ
njb-229	15	63	risk	risk	NOUN
njb-229	15	64	factors	factor	NOUN
njb-229	15	65	in	in	ADP
njb-229	15	66	healthcare	healthcare	NOUN
njb-229	15	67	settings	setting	NOUN
njb-229	15	68	[	[	X
njb-229	15	69	1	1	NUM
njb-229	15	70	]	]	PUNCT
njb-229	15	71	but	but	CCONJ
njb-229	15	72	also	also	ADV
njb-229	15	73	from	from	ADP
njb-229	15	74	immunocompetent	immunocompetent	ADJ
njb-229	15	75	individuals	individual	NOUN
njb-229	15	76	causing	cause	VERB
njb-229	15	77	a	a	DET
njb-229	15	78	wide	wide	ADJ
njb-229	15	79	range	range	NOUN
njb-229	15	80	of	of	ADP
njb-229	15	81	infections	infection	NOUN
njb-229	15	82	mostly	mostly	ADV
njb-229	15	83	urinary	urinary	ADJ
njb-229	15	84	tract	tract	NOUN
njb-229	15	85	infection	infection	NOUN
njb-229	15	86	,	,	PUNCT
njb-229	15	87	pyogenic	pyogenic	ADJ
njb-229	15	88	liver	liver	NOUN
njb-229	15	89	abscess	abscess	NOUN
njb-229	15	90	,	,	PUNCT
njb-229	15	91	necrotizing	necrotize	VERB
njb-229	15	92	pneumonia	pneumonia	NOUN
njb-229	15	93	or	or	CCONJ
njb-229	15	94	other	other	ADJ
njb-229	15	95	life	life	NOUN
njb-229	15	96	-	-	PUNCT
njb-229	15	97	threatening	threaten	VERB
njb-229	15	98	infections	infection	NOUN
njb-229	15	99	[	[	X
njb-229	15	100	2	2	NUM
njb-229	15	101	]	]	X
njb-229	15	102	.	.	PUNCT
njb-229	16	1	management	management	NOUN
njb-229	16	2	of	of	ADP
njb-229	16	3	its	its	PRON
njb-229	16	4	infection	infection	NOUN
njb-229	16	5	becomes	become	VERB
njb-229	16	6	complicated	complicated	ADJ
njb-229	16	7	after	after	SCONJ
njb-229	16	8	it	it	PRON
njb-229	16	9	is	be	AUX
njb-229	16	10	found	find	VERB
njb-229	16	11	to	to	PART
njb-229	16	12	be	be	AUX
njb-229	16	13	not	not	PART
njb-229	16	14	susceptible	susceptible	ADJ
njb-229	16	15	to	to	ADP
njb-229	16	16	the	the	DET
njb-229	16	17	third	third	ADJ
njb-229	16	18	-	-	PUNCT
njb-229	16	19	generation	generation	NOUN
njb-229	16	20	cephalosporin	cephalosporin	NOUN
njb-229	16	21	antibiotics	antibiotic	NOUN
njb-229	16	22	,	,	PUNCT
njb-229	16	23	including	include	VERB
njb-229	16	24	monobactams	monobactam	NOUN
njb-229	17	1	[	[	PUNCT
njb-229	17	2	3	3	NUM
njb-229	17	3	]	]	PUNCT
njb-229	17	4	.	.	PUNCT
njb-229	18	1	this	this	PRON
njb-229	18	2	is	be	AUX
njb-229	18	3	further	far	ADV
njb-229	18	4	aggravated	aggravate	VERB
njb-229	18	5	by	by	ADP
njb-229	18	6	the	the	DET
njb-229	18	7	non	non	NOUN
njb-229	18	8	-	-	NOUN
njb-229	18	9	response	response	NOUN
njb-229	18	10	of	of	ADP
njb-229	18	11	carbapenem	carbapenem	PROPN
njb-229	18	12	antibiotics	antibiotic	NOUN
njb-229	18	13	through	through	ADP
njb-229	18	14	either	either	CCONJ
njb-229	18	15	the	the	DET
njb-229	18	16	expression	expression	NOUN
njb-229	18	17	of	of	ADP
njb-229	18	18	carbapenemase	carbapenemase	NOUN
njb-229	18	19	enzymes	enzyme	NOUN
njb-229	18	20	that	that	PRON
njb-229	18	21	make	make	VERB
njb-229	18	22	bacteria	bacteria	NOUN
njb-229	18	23	almost	almost	ADV
njb-229	18	24	resistant	resistant	ADJ
njb-229	18	25	to	to	ADP
njb-229	18	26	a	a	DET
njb-229	18	27	β	β	NOUN
njb-229	18	28	-	-	PUNCT
njb-229	18	29	lactam	lactam	NOUN
njb-229	18	30	group	group	NOUN
njb-229	18	31	antibiotic	antibiotic	NOUN
njb-229	18	32	[	[	PUNCT
njb-229	18	33	4	4	NUM
njb-229	18	34	,	,	PUNCT
njb-229	18	35	5	5	NUM
njb-229	18	36	]	]	PUNCT
njb-229	18	37	or	or	CCONJ
njb-229	18	38	alteration	alteration	NOUN
njb-229	18	39	of	of	ADP
njb-229	18	40	permeability	permeability	NOUN
njb-229	18	41	due	due	ADP
njb-229	18	42	to	to	ADP
njb-229	18	43	loss	loss	NOUN
njb-229	18	44	of	of	ADP
njb-229	18	45	porin	porin	NOUN
njb-229	18	46	or	or	CCONJ
njb-229	18	47	overexpression	overexpression	NOUN
njb-229	18	48	of	of	ADP
njb-229	18	49	the	the	DET
njb-229	18	50	efflux	efflux	NOUN
njb-229	18	51	pump	pump	NOUN
njb-229	18	52	[	[	PUNCT
njb-229	18	53	5	5	NUM
njb-229	18	54	,	,	PUNCT
njb-229	18	55	6	6	NUM
njb-229	18	56	]	]	PUNCT
njb-229	18	57	.	.	PUNCT
njb-229	19	1	therefore	therefore	ADV
njb-229	19	2	,	,	PUNCT
njb-229	19	3	who	who	PRON
njb-229	19	4	prioritizes	prioritize	VERB
njb-229	19	5	extended	extend	VERB
njb-229	19	6	-	-	PUNCT
njb-229	19	7	spectrum	spectrum	NOUN
njb-229	19	8	β	β	NOUN
njb-229	19	9	-	-	PUNCT
njb-229	19	10	lactamase	lactamase	NOUN
njb-229	19	11	[	[	X
njb-229	19	12	esbl	esbl	X
njb-229	19	13	]	]	PUNCT
njb-229	19	14	and	and	CCONJ
njb-229	19	15	carbapenemresistant	carbapenemresistant	PROPN
njb-229	19	16	klebsiella	klebsiella	PROPN
njb-229	19	17	pneumoniae	pneumoniae	PROPN
njb-229	20	1	[	[	X
njb-229	20	2	crkp	crkp	X
njb-229	20	3	]	]	X
njb-229	20	4	as	as	ADP
njb-229	20	5	a	a	DET
njb-229	20	6	critical	critical	ADJ
njb-229	20	7	public	public	ADJ
njb-229	20	8	health	health	NOUN
njb-229	20	9	threat	threat	NOUN
njb-229	20	10	[	[	PUNCT
njb-229	20	11	7	7	NUM
njb-229	20	12	]	]	PUNCT
njb-229	20	13	.	.	PUNCT
njb-229	21	1	the	the	DET
njb-229	21	2	epidemiological	epidemiological	ADJ
njb-229	21	3	distribution	distribution	NOUN
njb-229	21	4	of	of	ADP
njb-229	21	5	crkp	crkp	PROPN
njb-229	21	6	fluctuates	fluctuate	VERB
njb-229	21	7	in	in	ADP
njb-229	21	8	all	all	DET
njb-229	21	9	countries	country	NOUN
njb-229	21	10	[	[	X
njb-229	21	11	8	8	NUM
njb-229	21	12	]	]	PUNCT
njb-229	21	13	with	with	ADP
njb-229	21	14	significantly	significantly	ADV
njb-229	21	15	higher	high	ADJ
njb-229	21	16	morbidity	morbidity	NOUN
njb-229	21	17	and	and	CCONJ
njb-229	21	18	mortality	mortality	NOUN
njb-229	21	19	rate	rate	NOUN
njb-229	21	20	than	than	ADP
njb-229	21	21	those	those	PRON
njb-229	21	22	of	of	ADP
njb-229	21	23	carbapenem	carbapenem	PROPN
njb-229	21	24	susceptible	susceptible	ADJ
njb-229	21	25	k.	k.	NOUN
njb-229	21	26	pneumoniae	pneumoniae	NOUN
njb-229	21	27	,	,	PUNCT
njb-229	21	28	which	which	PRON
njb-229	21	29	initiates	initiate	VERB
njb-229	21	30	devastating	devastating	ADJ
njb-229	21	31	public	public	ADJ
njb-229	21	32	health	health	NOUN
njb-229	21	33	conditions	condition	NOUN
njb-229	21	34	[	[	X
njb-229	21	35	9	9	NUM
njb-229	21	36	]	]	PUNCT
njb-229	21	37	.	.	PUNCT
njb-229	22	1	this	this	DET
njb-229	22	2	bacterium	bacterium	NOUN
njb-229	22	3	notoriety	notoriety	NOUN
njb-229	22	4	gained	gain	VERB
njb-229	22	5	its	its	PRON
njb-229	22	6	name	name	NOUN
njb-229	22	7	among	among	ADP
njb-229	22	8	antibiotic	antibiotic	ADJ
njb-229	22	9	-	-	PUNCT
njb-229	22	10	resistant	resistant	ADJ
njb-229	22	11	bacteria	bacteria	NOUN
njb-229	22	12	.	.	PUNCT
njb-229	23	1	the	the	DET
njb-229	23	2	european	european	ADJ
njb-229	23	3	antimicrobial	antimicrobial	ADJ
njb-229	23	4	resistance	resistance	NOUN
njb-229	23	5	surveillance	surveillance	NOUN
njb-229	23	6	network	network	NOUN
njb-229	23	7	(	(	PUNCT
njb-229	23	8	ears	ear	NOUN
njb-229	23	9	-	-	PUNCT
njb-229	23	10	net	net	NOUN
njb-229	23	11	)	)	PUNCT
njb-229	23	12	showed	show	VERB
njb-229	23	13	that	that	SCONJ
njb-229	23	14	from	from	ADP
njb-229	23	15	2005	2005	NUM
njb-229	23	16	the	the	DET
njb-229	23	17	non	non	ADJ
njb-229	23	18	-	-	ADJ
njb-229	23	19	susceptibility	susceptibility	ADJ
njb-229	23	20	rate	rate	NOUN
njb-229	23	21	of	of	ADP
njb-229	23	22	this	this	DET
njb-229	23	23	bacterium	bacterium	NOUN
njb-229	23	24	had	have	AUX
njb-229	23	25	increased	increase	VERB
njb-229	23	26	significantly	significantly	ADV
njb-229	23	27	against	against	ADP
njb-229	23	28	thirdgeneration	thirdgeneration	NOUN
njb-229	23	29	cephalosporins	cephalosporin	NOUN
njb-229	23	30	,	,	PUNCT
njb-229	23	31	aminoglycosides	aminoglycoside	NOUN
njb-229	23	32	,	,	PUNCT
njb-229	23	33	fluoroquinolones	fluoroquinolone	NOUN
njb-229	23	34	,	,	PUNCT
njb-229	23	35	and	and	CCONJ
njb-229	23	36	carbapenems	carbapenem	NOUN
njb-229	23	37	that	that	PRON
njb-229	23	38	have	have	VERB
njb-229	23	39	greater	great	ADJ
njb-229	23	40	variation	variation	NOUN
njb-229	23	41	in	in	ADP
njb-229	23	42	different	different	ADJ
njb-229	23	43	countries	country	NOUN
njb-229	23	44	of	of	ADP
njb-229	23	45	the	the	DET
njb-229	23	46	european	european	PROPN
njb-229	23	47	union	union	PROPN
njb-229	24	1	[	[	PUNCT
njb-229	24	2	10	10	NUM
njb-229	24	3	]	]	PUNCT
njb-229	24	4	and	and	CCONJ
njb-229	24	5	other	other	ADJ
njb-229	24	6	parts	part	NOUN
njb-229	24	7	of	of	ADP
njb-229	24	8	the	the	DET
njb-229	24	9	world	world	NOUN
njb-229	24	10	,	,	PUNCT
njb-229	24	11	increasing	increase	VERB
njb-229	24	12	global	global	ADJ
njb-229	24	13	public	public	ADJ
njb-229	24	14	health	health	NOUN
njb-229	24	15	concerns	concern	NOUN
njb-229	24	16	[	[	X
njb-229	24	17	11	11	NUM
njb-229	24	18	]	]	PUNCT
njb-229	24	19	.	.	PUNCT
njb-229	25	1	hence	hence	ADV
njb-229	25	2	,	,	PUNCT
njb-229	25	3	who	who	PRON
njb-229	25	4	recognized	recognize	VERB
njb-229	25	5	this	this	DET
njb-229	25	6	bacterium	bacterium	NOUN
njb-229	25	7	with	with	ADP
njb-229	25	8	acinetobacter	acinetobacter	ADJ
njb-229	25	9	baumannii	baumannii	NOUN
njb-229	25	10	,	,	PUNCT
njb-229	25	11	pseudomonas	pseudomonas	PROPN
njb-229	25	12	aeruginosa	aeruginosa	PROPN
njb-229	25	13	as	as	ADP
njb-229	25	14	a	a	DET
njb-229	25	15	who	who	PRON
njb-229	25	16	priority	priority	NOUN
njb-229	25	17	pathogen	pathogen	PROPN
njb-229	25	18	list	list	NOUN
njb-229	25	19	for	for	ADP
njb-229	25	20	“	"	PUNCT
njb-229	25	21	research	research	NOUN
njb-229	25	22	and	and	CCONJ
njb-229	25	23	development	development	NOUN
njb-229	25	24	”	"	PUNCT
njb-229	25	25	of	of	ADP
njb-229	25	26	new	new	ADJ
njb-229	25	27	antibiotics	antibiotic	NOUN
njb-229	25	28	[	[	PUNCT
njb-229	25	29	7	7	NUM
njb-229	25	30	]	]	X
njb-229	25	31	.	.	PUNCT
njb-229	26	1	therefore	therefore	ADV
njb-229	26	2	,	,	PUNCT
njb-229	26	3	this	this	DET
njb-229	26	4	study	study	NOUN
njb-229	26	5	was	be	AUX
njb-229	26	6	carried	carry	VERB
njb-229	26	7	out	out	ADP
njb-229	26	8	to	to	PART
njb-229	26	9	find	find	VERB
njb-229	26	10	out	out	ADP
njb-229	26	11	the	the	DET
njb-229	26	12	frequency	frequency	NOUN
njb-229	26	13	of	of	ADP
njb-229	26	14	crkp	crkp	PROPN
njb-229	26	15	along	along	ADP
njb-229	26	16	with	with	ADP
njb-229	26	17	their	their	PRON
njb-229	26	18	antibiotic	antibiotic	ADJ
njb-229	26	19	susceptibility	susceptibility	NOUN
njb-229	26	20	profile	profile	NOUN
njb-229	26	21	and	and	CCONJ
njb-229	26	22	mic	mic	ADJ
njb-229	26	23	nepal	nepal	ADJ
njb-229	26	24	journal	journal	NOUN
njb-229	26	25	of	of	ADP
njb-229	26	26	biotechnology	biotechnology	NOUN
njb-229	26	27	publisher	publisher	NOUN
njb-229	26	28	:	:	PUNCT
njb-229	26	29	biotechnology	biotechnology	NOUN
njb-229	26	30	society	society	NOUN
njb-229	26	31	of	of	ADP
njb-229	26	32	nepal	nepal	PROPN
njb-229	26	33	issn	issn	PROPN
njb-229	26	34	(	(	PUNCT
njb-229	26	35	online	online	ADV
njb-229	26	36	):	):	PUNCT
njb-229	26	37	2467	2467	NUM
njb-229	26	38	-	-	SYM
njb-229	26	39	9313	9313	NUM
njb-229	26	40	journal	journal	NOUN
njb-229	26	41	homepage	homepage	NOUN
njb-229	26	42	:	:	PUNCT
njb-229	26	43	https://nepjb.com/index.php/njb	https://nepjb.com/index.php/njb	PROPN
njb-229	26	44	issn	issn	PROPN
njb-229	26	45	(	(	PUNCT
njb-229	26	46	print	print	NOUN
njb-229	26	47	):	):	PUNCT
njb-229	26	48	2091	2091	NUM
njb-229	26	49	-	-	SYM
njb-229	26	50	1130	1130	NUM
njb-229	26	51	https://orcid.org/0000-0003-3398-7422	https://orcid.org/0000-0003-3398-7422	NOUN
njb-229	26	52	mailto:mahaju@gmail.com	mailto:mahaju@gmail.com	PROPN
njb-229	26	53	nepal	nepal	PROPN
njb-229	26	54	j	j	PROPN
njb-229	26	55	biotechnol	biotechnol	PROPN
njb-229	26	56	.	.	PUNCT
njb-229	27	1	2	2	NUM
njb-229	27	2	0	0	NUM
njb-229	27	3	2	2	NUM
njb-229	27	4	2	2	NUM
njb-229	27	5	j	j	NOUN
njb-229	27	6	u	u	NOUN
njb-229	27	7	l	l	NOUN
njb-229	27	8	;	;	PUNCT
njb-229	27	9	1	1	NUM
njb-229	27	10	0	0	NUM
njb-229	27	11	(	(	PUNCT
njb-229	27	12	1):4	1):4	NUM
njb-229	27	13	0	0	NUM
njb-229	27	14	4	4	NUM
njb-229	27	15	4	4	NUM
njb-229	27	16	saud	saud	PROPN
njb-229	27	17	et	et	PROPN
njb-229	27	18	al	al	PROPN
njb-229	27	19	.	.	PUNCT
njb-229	28	1	©	©	PROPN
njb-229	28	2	njb	njb	PROPN
njb-229	28	3	,	,	PUNCT
njb-229	28	4	bsn	bsn	PROPN
njb-229	28	5	41	41	NUM
njb-229	28	6	of	of	ADP
njb-229	28	7	imipenem	imipenem	PROPN
njb-229	28	8	for	for	ADP
njb-229	28	9	screened	screen	VERB
njb-229	28	10	carbapenem	carbapenem	NOUN
njb-229	28	11	-	-	PUNCT
njb-229	28	12	resistant	resistant	ADJ
njb-229	28	13	and	and	CCONJ
njb-229	28	14	intermediate	intermediate	ADJ
njb-229	28	15	isolates	isolate	NOUN
njb-229	28	16	.	.	PUNCT
njb-229	29	1	materials	material	NOUN
njb-229	29	2	and	and	CCONJ
njb-229	29	3	methods	method	NOUN
njb-229	29	4	it	it	PRON
njb-229	29	5	is	be	AUX
njb-229	29	6	a	a	DET
njb-229	29	7	hospital	hospital	NOUN
njb-229	29	8	-	-	PUNCT
njb-229	29	9	based	base	VERB
njb-229	29	10	prospective	prospective	ADJ
njb-229	29	11	cross	cross	ADJ
njb-229	29	12	-	-	ADJ
njb-229	29	13	sectional	sectional	ADJ
njb-229	29	14	study	study	NOUN
njb-229	29	15	;	;	PUNCT
njb-229	29	16	carried	carry	VERB
njb-229	29	17	out	out	ADP
njb-229	29	18	in	in	ADP
njb-229	29	19	the	the	DET
njb-229	29	20	microbiology	microbiology	NOUN
njb-229	29	21	department	department	NOUN
njb-229	29	22	of	of	ADP
njb-229	29	23	b	b	PROPN
njb-229	29	24	and	and	CCONJ
njb-229	29	25	b	b	PROPN
njb-229	29	26	hospital	hospital	NOUN
njb-229	29	27	,	,	PUNCT
njb-229	29	28	nepal	nepal	ADJ
njb-229	29	29	,	,	PUNCT
njb-229	29	30	from	from	ADP
njb-229	29	31	15	15	NUM
njb-229	29	32	july	july	NOUN
njb-229	29	33	2018	2018	NUM
njb-229	29	34	to	to	ADP
njb-229	29	35	15	15	NUM
njb-229	29	36	october	october	PROPN
njb-229	29	37	2018	2018	NUM
njb-229	29	38	.	.	PUNCT
njb-229	30	1	the	the	DET
njb-229	30	2	target	target	NOUN
njb-229	30	3	group	group	NOUN
njb-229	30	4	of	of	ADP
njb-229	30	5	this	this	DET
njb-229	30	6	study	study	NOUN
njb-229	30	7	was	be	AUX
njb-229	30	8	irrespective	irrespective	ADJ
njb-229	30	9	of	of	ADP
njb-229	30	10	sex	sex	NOUN
njb-229	30	11	,	,	PUNCT
njb-229	30	12	all	all	DET
njb-229	30	13	age	age	NOUN
njb-229	30	14	groups	group	NOUN
njb-229	30	15	of	of	ADP
njb-229	30	16	patients	patient	NOUN
njb-229	30	17	attending	attend	VERB
njb-229	30	18	the	the	DET
njb-229	30	19	hospital	hospital	NOUN
njb-229	30	20	for	for	ADP
njb-229	30	21	medical	medical	ADJ
njb-229	30	22	treatment	treatment	NOUN
njb-229	30	23	.	.	PUNCT
njb-229	31	1	all	all	DET
njb-229	31	2	collected	collect	VERB
njb-229	31	3	data	datum	NOUN
njb-229	31	4	were	be	AUX
njb-229	31	5	entered	enter	VERB
njb-229	31	6	and	and	CCONJ
njb-229	31	7	analyzed	analyze	VERB
njb-229	31	8	using	use	VERB
njb-229	31	9	spss	spss	PROPN
njb-229	31	10	v17.0	v17.0	PROPN
njb-229	31	11	.	.	PUNCT
njb-229	32	1	ethical	ethical	ADJ
njb-229	32	2	consent	consent	NOUN
njb-229	32	3	was	be	AUX
njb-229	32	4	obtained	obtain	VERB
njb-229	32	5	from	from	ADP
njb-229	32	6	the	the	DET
njb-229	32	7	nobel	nobel	PROPN
njb-229	32	8	institutional	institutional	PROPN
njb-229	32	9	review	review	PROPN
njb-229	32	10	committee	committee	PROPN
njb-229	32	11	(	(	PUNCT
njb-229	32	12	irc	irc	PROPN
njb-229	32	13	)	)	PUNCT
njb-229	32	14	.	.	PUNCT
njb-229	33	1	bacterial	bacterial	ADJ
njb-229	33	2	isolation	isolation	NOUN
njb-229	33	3	and	and	CCONJ
njb-229	33	4	identification	identification	NOUN
njb-229	33	5	samples	sample	NOUN
njb-229	33	6	(	(	PUNCT
njb-229	33	7	blood	blood	NOUN
njb-229	33	8	,	,	PUNCT
njb-229	33	9	pus	pus	NOUN
njb-229	33	10	,	,	PUNCT
njb-229	33	11	urine	urine	NOUN
njb-229	33	12	,	,	PUNCT
njb-229	33	13	respiratory	respiratory	ADJ
njb-229	33	14	specimen	speciman	NOUN
njb-229	33	15	,	,	PUNCT
njb-229	33	16	catheter	catheter	NOUN
njb-229	33	17	tips	tip	NOUN
njb-229	33	18	,	,	PUNCT
njb-229	33	19	and	and	CCONJ
njb-229	33	20	joint	joint	ADJ
njb-229	33	21	fluid	fluid	NOUN
njb-229	33	22	)	)	PUNCT
njb-229	33	23	were	be	AUX
njb-229	33	24	collected	collect	VERB
njb-229	33	25	aseptically	aseptically	ADV
njb-229	33	26	according	accord	VERB
njb-229	33	27	to	to	ADP
njb-229	33	28	standard	standard	ADJ
njb-229	33	29	microbiological	microbiological	ADJ
njb-229	33	30	guidelines	guideline	NOUN
njb-229	33	31	[	[	X
njb-229	33	32	12	12	NUM
njb-229	33	33	]	]	PUNCT
njb-229	33	34	.	.	PUNCT
njb-229	34	1	good	good	ADJ
njb-229	34	2	quality	quality	NOUN
njb-229	34	3	specimens	specimen	NOUN
njb-229	34	4	were	be	AUX
njb-229	34	5	accepted	accept	VERB
njb-229	34	6	,	,	PUNCT
njb-229	34	7	while	while	SCONJ
njb-229	34	8	unlabeled	unlabele	VERB
njb-229	34	9	or	or	CCONJ
njb-229	34	10	mislabeled	mislabeled	ADJ
njb-229	34	11	specimens	specimen	NOUN
njb-229	34	12	,	,	PUNCT
njb-229	34	13	dry	dry	ADJ
njb-229	34	14	swabs	swab	NOUN
njb-229	34	15	,	,	PUNCT
njb-229	34	16	specimens	specimen	NOUN
njb-229	34	17	that	that	PRON
njb-229	34	18	leak	leak	VERB
njb-229	34	19	from	from	ADP
njb-229	34	20	a	a	DET
njb-229	34	21	container	container	NOUN
njb-229	34	22	,	,	PUNCT
njb-229	34	23	delay	delay	NOUN
njb-229	34	24	in	in	ADP
njb-229	34	25	specimen	speciman	NOUN
njb-229	34	26	transport	transport	NOUN
njb-229	34	27	,	,	PUNCT
njb-229	34	28	and	and	CCONJ
njb-229	34	29	inappropriately	inappropriately	ADV
njb-229	34	30	stored	store	VERB
njb-229	34	31	samples	sample	NOUN
njb-229	34	32	were	be	AUX
njb-229	34	33	excluded	exclude	VERB
njb-229	34	34	from	from	ADP
njb-229	34	35	this	this	DET
njb-229	34	36	study	study	NOUN
njb-229	34	37	.	.	PUNCT
njb-229	35	1	all	all	DET
njb-229	35	2	samples	sample	NOUN
njb-229	35	3	,	,	PUNCT
njb-229	35	4	except	except	SCONJ
njb-229	35	5	blood	blood	NOUN
njb-229	35	6	,	,	PUNCT
njb-229	35	7	were	be	AUX
njb-229	35	8	cultured	cultured	ADJ
njb-229	35	9	on	on	ADP
njb-229	35	10	blood	blood	NOUN
njb-229	35	11	agar	agar	NOUN
njb-229	35	12	and	and	CCONJ
njb-229	35	13	macconkey	macconkey	NOUN
njb-229	35	14	agar	agar	NOUN
njb-229	35	15	;	;	PUNCT
njb-229	35	16	incubated	incubate	VERB
njb-229	35	17	at	at	ADP
njb-229	35	18	370c	370c	NUM
njb-229	35	19	overnight	overnight	ADV
njb-229	35	20	,	,	PUNCT
njb-229	35	21	and	and	CCONJ
njb-229	35	22	identified	identify	VERB
njb-229	35	23	as	as	ADP
njb-229	35	24	k.	k.	NOUN
njb-229	35	25	pneumoniae	pneumoniae	NOUN
njb-229	35	26	using	use	VERB
njb-229	35	27	gram	gram	NOUN
njb-229	35	28	staining	staining	NOUN
njb-229	35	29	and	and	CCONJ
njb-229	35	30	conventional	conventional	ADJ
njb-229	35	31	biochemical	biochemical	ADJ
njb-229	35	32	tests	test	NOUN
njb-229	35	33	(	(	PUNCT
njb-229	35	34	catalase	catalase	PROPN
njb-229	35	35	,	,	PUNCT
njb-229	35	36	oxidase	oxidase	NOUN
njb-229	35	37	,	,	PUNCT
njb-229	35	38	indole	indole	ADJ
njb-229	35	39	test	test	NOUN
njb-229	35	40	,	,	PUNCT
njb-229	35	41	motility	motility	NOUN
njb-229	35	42	,	,	PUNCT
njb-229	35	43	citrate	citrate	NOUN
njb-229	35	44	utilization	utilization	NOUN
njb-229	35	45	,	,	PUNCT
njb-229	35	46	triple	triple	ADJ
njb-229	35	47	sugar	sugar	NOUN
njb-229	35	48	iron	iron	NOUN
njb-229	35	49	utilization	utilization	NOUN
njb-229	35	50	and	and	CCONJ
njb-229	35	51	urease	urease	NOUN
njb-229	35	52	test	test	NOUN
njb-229	35	53	)	)	PUNCT
njb-229	36	1	[	[	X
njb-229	36	2	13	13	NUM
njb-229	36	3	]	]	PUNCT
njb-229	36	4	.	.	PUNCT
njb-229	37	1	the	the	DET
njb-229	37	2	reagents	reagent	NOUN
njb-229	37	3	and	and	CCONJ
njb-229	37	4	culture	culture	NOUN
njb-229	37	5	media	medium	NOUN
njb-229	37	6	were	be	AUX
njb-229	37	7	purchased	purchase	VERB
njb-229	37	8	from	from	ADP
njb-229	37	9	himedia	himedia	PROPN
njb-229	37	10	laboratories	laboratory	NOUN
njb-229	37	11	,	,	PUNCT
njb-229	37	12	india	india	PROPN
njb-229	37	13	.	.	PUNCT
njb-229	38	1	the	the	DET
njb-229	38	2	bd	bd	PROPN
njb-229	38	3	™	™	PROPN
njb-229	38	4	bactec	bactec	VERB
njb-229	38	5	™	™	NOUN
njb-229	39	1	fx40	fx40	NOUN
njb-229	39	2	automated	automate	VERB
njb-229	39	3	blood	blood	NOUN
njb-229	39	4	culture	culture	NOUN
njb-229	39	5	system	system	NOUN
njb-229	39	6	was	be	AUX
njb-229	39	7	used	use	VERB
njb-229	39	8	for	for	ADP
njb-229	39	9	blood	blood	NOUN
njb-229	39	10	culture	culture	NOUN
njb-229	39	11	,	,	PUNCT
njb-229	39	12	and	and	CCONJ
njb-229	39	13	a	a	DET
njb-229	39	14	positive	positive	ADJ
njb-229	39	15	culture	culture	NOUN
njb-229	39	16	bottle	bottle	NOUN
njb-229	39	17	was	be	AUX
njb-229	39	18	further	far	ADV
njb-229	39	19	subcultured	subculture	VERB
njb-229	39	20	on	on	ADP
njb-229	39	21	blood	blood	NOUN
njb-229	39	22	agar	agar	NOUN
njb-229	39	23	and	and	CCONJ
njb-229	39	24	macconkey	macconkey	NOUN
njb-229	39	25	as	as	ADP
njb-229	39	26	previously	previously	ADV
njb-229	39	27	for	for	ADP
njb-229	39	28	identification	identification	NOUN
njb-229	39	29	[	[	PUNCT
njb-229	39	30	13	13	NUM
njb-229	39	31	]	]	PUNCT
njb-229	39	32	.	.	PUNCT
njb-229	40	1	antibiotic	antibiotic	ADJ
njb-229	40	2	susceptibility	susceptibility	NOUN
njb-229	40	3	test	test	VERB
njb-229	40	4	the	the	DET
njb-229	40	5	antibiotic	antibiotic	ADJ
njb-229	40	6	susceptibility	susceptibility	NOUN
njb-229	40	7	test	test	NOUN
njb-229	40	8	was	be	AUX
njb-229	40	9	performed	perform	VERB
njb-229	40	10	following	follow	VERB
njb-229	40	11	clsi	clsi	NOUN
njb-229	40	12	guidelines	guideline	NOUN
njb-229	40	13	2018	2018	NUM
njb-229	40	14	through	through	ADP
njb-229	40	15	the	the	DET
njb-229	40	16	disc	disc	NOUN
njb-229	40	17	diffusion	diffusion	NOUN
njb-229	40	18	method	method	NOUN
njb-229	40	19	.	.	PUNCT
njb-229	41	1	eleven	eleven	NUM
njb-229	41	2	different	different	ADJ
njb-229	41	3	antibiotics	antibiotic	NOUN
njb-229	41	4	(	(	PUNCT
njb-229	41	5	himedia	himedia	PROPN
njb-229	41	6	laboratories	laboratories	PROPN
njb-229	41	7	,	,	PUNCT
njb-229	41	8	india	india	PROPN
njb-229	41	9	)	)	PUNCT
njb-229	41	10	;	;	PUNCT
njb-229	41	11	amikacin	amikacin	PROPN
njb-229	41	12	(	(	PUNCT
njb-229	41	13	30	30	NUM
njb-229	41	14	µg	µg	NOUN
njb-229	41	15	)	)	PUNCT
njb-229	41	16	,	,	PUNCT
njb-229	41	17	cefepime	cefepime	ADV
njb-229	41	18	(	(	PUNCT
njb-229	41	19	30	30	NUM
njb-229	41	20	µg	µg	NOUN
njb-229	41	21	)	)	PUNCT
njb-229	41	22	,	,	PUNCT
njb-229	41	23	ceftriaxone	ceftriaxone	PROPN
njb-229	41	24	(	(	PUNCT
njb-229	41	25	30	30	NUM
njb-229	41	26	µg	µg	NOUN
njb-229	41	27	)	)	PUNCT
njb-229	41	28	,	,	PUNCT
njb-229	41	29	ciprofloxacin	ciprofloxacin	NOUN
njb-229	41	30	(	(	PUNCT
njb-229	41	31	5	5	NUM
njb-229	41	32	µg	µg	NOUN
njb-229	41	33	)	)	PUNCT
njb-229	41	34	,	,	PUNCT
njb-229	41	35	chloramphenicol	chloramphenicol	NOUN
njb-229	41	36	(	(	PUNCT
njb-229	41	37	30	30	NUM
njb-229	41	38	µg	µg	NOUN
njb-229	41	39	)	)	PUNCT
njb-229	41	40	,	,	PUNCT
njb-229	41	41	cotrimoxazole	cotrimoxazole	PROPN
njb-229	41	42	(	(	PUNCT
njb-229	41	43	25	25	NUM
njb-229	41	44	µg	µg	NOUN
njb-229	41	45	)	)	PUNCT
njb-229	41	46	,	,	PUNCT
njb-229	41	47	gentamicin	gentamicin	PROPN
njb-229	41	48	(	(	PUNCT
njb-229	41	49	10	10	NUM
njb-229	41	50	µg	µg	NOUN
njb-229	41	51	)	)	PUNCT
njb-229	41	52	,	,	PUNCT
njb-229	41	53	nitrofurantoin	nitrofurantoin	NOUN
njb-229	41	54	(	(	PUNCT
njb-229	41	55	300	300	NUM
njb-229	41	56	µg	µg	NOUN
njb-229	41	57	)	)	PUNCT
njb-229	41	58	,	,	PUNCT
njb-229	41	59	piperacillintazobactam	piperacillintazobactam	NOUN
njb-229	41	60	(	(	PUNCT
njb-229	41	61	100/10	100/10	NUM
njb-229	41	62	µg	µg	NOUN
njb-229	41	63	)	)	PUNCT
njb-229	41	64	,	,	PUNCT
njb-229	41	65	and	and	CCONJ
njb-229	41	66	ofloxacin	ofloxacin	NOUN
njb-229	41	67	(	(	PUNCT
njb-229	41	68	5	5	NUM
njb-229	41	69	µg	µg	NOUN
njb-229	41	70	)	)	PUNCT
njb-229	41	71	were	be	AUX
njb-229	41	72	tested	test	VERB
njb-229	41	73	in	in	ADP
njb-229	41	74	isolated	isolated	ADJ
njb-229	41	75	klebsiella	klebsiella	PROPN
njb-229	41	76	pneumoniae	pneumoniae	NOUN
njb-229	41	77	.	.	PUNCT
njb-229	42	1	the	the	DET
njb-229	42	2	bacterium	bacterium	NOUN
njb-229	42	3	showing	show	VERB
njb-229	42	4	resistance	resistance	NOUN
njb-229	42	5	to	to	ADP
njb-229	42	6	at	at	ADV
njb-229	42	7	least	least	ADV
njb-229	42	8	one	one	NUM
njb-229	42	9	antibiotic	antibiotic	NOUN
njb-229	42	10	from	from	ADP
njb-229	42	11	three	three	NUM
njb-229	42	12	or	or	CCONJ
njb-229	42	13	more	more	ADJ
njb-229	42	14	than	than	ADP
njb-229	42	15	three	three	NUM
njb-229	42	16	different	different	ADJ
njb-229	42	17	classes	class	NOUN
njb-229	42	18	was	be	AUX
njb-229	42	19	categorized	categorize	VERB
njb-229	42	20	as	as	ADP
njb-229	42	21	multidrug	multidrug	NOUN
njb-229	42	22	resistance	resistance	NOUN
njb-229	42	23	[	[	X
njb-229	42	24	14	14	NUM
njb-229	42	25	]	]	PUNCT
njb-229	42	26	.	.	PUNCT
njb-229	43	1	the	the	DET
njb-229	43	2	resistance	resistance	NOUN
njb-229	43	3	to	to	ADP
njb-229	43	4	carbapenem	carbapenem	PROPN
njb-229	43	5	was	be	AUX
njb-229	43	6	screened	screen	VERB
njb-229	43	7	using	use	VERB
njb-229	43	8	ertapenem	ertapenem	PROPN
njb-229	43	9	(	(	PUNCT
njb-229	43	10	10μg	10μg	PROPN
njb-229	43	11	)	)	PUNCT
njb-229	43	12	disc	disc	NOUN
njb-229	43	13	.	.	PUNCT
njb-229	44	1	according	accord	VERB
njb-229	44	2	to	to	ADP
njb-229	44	3	zone	zone	NOUN
njb-229	44	4	size	size	NOUN
njb-229	44	5	diameter	diameter	NOUN
njb-229	44	6	,	,	PUNCT
njb-229	44	7	isolates	isolate	NOUN
njb-229	44	8	were	be	AUX
njb-229	44	9	differentiated	differentiate	VERB
njb-229	44	10	as	as	ADP
njb-229	44	11	sensitive	sensitive	ADJ
njb-229	44	12	,	,	PUNCT
njb-229	44	13	intermediate	intermediate	ADJ
njb-229	44	14	,	,	PUNCT
njb-229	44	15	and	and	CCONJ
njb-229	44	16	resistant	resistant	ADJ
njb-229	44	17	with	with	ADP
njb-229	44	18	zone	zone	NOUN
njb-229	44	19	size	size	NOUN
njb-229	44	20	inhibition	inhibition	NOUN
njb-229	44	21	≥22	≥22	INTJ
njb-229	44	22	mm	mm	INTJ
njb-229	44	23	,	,	PUNCT
njb-229	44	24	19	19	NUM
njb-229	44	25	-	-	SYM
njb-229	44	26	21	21	NUM
njb-229	44	27	mm	mm	PROPN
njb-229	44	28	,	,	PUNCT
njb-229	44	29	and	and	CCONJ
njb-229	44	30	≤18	≤18	ADJ
njb-229	44	31	mm	mm	INTJ
njb-229	44	32	,	,	PUNCT
njb-229	44	33	respectively	respectively	ADV
njb-229	44	34	[	[	X
njb-229	44	35	15	15	NUM
njb-229	44	36	]	]	PUNCT
njb-229	44	37	.	.	PUNCT
njb-229	45	1	the	the	DET
njb-229	45	2	minimum	minimum	ADJ
njb-229	45	3	inhibitory	inhibitory	ADJ
njb-229	45	4	concentration	concentration	NOUN
njb-229	45	5	(	(	PUNCT
njb-229	45	6	mic	mic	NOUN
njb-229	45	7	)	)	PUNCT
njb-229	45	8	of	of	ADP
njb-229	45	9	the	the	DET
njb-229	45	10	imipenem	imipenem	PROPN
njb-229	45	11	was	be	AUX
njb-229	45	12	tested	test	VERB
njb-229	45	13	for	for	ADP
njb-229	45	14	isolates	isolate	NOUN
njb-229	45	15	showing	show	VERB
njb-229	45	16	intermediate	intermediate	ADJ
njb-229	45	17	or	or	CCONJ
njb-229	45	18	resistance	resistance	NOUN
njb-229	45	19	to	to	ADP
njb-229	45	20	carbapenem	carbapenem	PROPN
njb-229	45	21	using	use	VERB
njb-229	45	22	the	the	DET
njb-229	45	23	imipenem	imipenem	PROPN
njb-229	45	24	ezy	ezy	PROPN
njb-229	45	25	mictm	mictm	PROPN
njb-229	45	26	strip	strip	PROPN
njb-229	45	27	following	follow	VERB
njb-229	45	28	the	the	DET
njb-229	45	29	manufacture	manufacture	NOUN
njb-229	45	30	instructions	instruction	NOUN
njb-229	45	31	(	(	PUNCT
njb-229	45	32	himedia	himedia	PROPN
njb-229	45	33	laboratories	laboratories	PROPN
njb-229	45	34	,	,	PUNCT
njb-229	45	35	india	india	PROPN
njb-229	45	36	)	)	PUNCT
njb-229	45	37	.	.	PUNCT
njb-229	46	1	the	the	DET
njb-229	46	2	mic	mic	NOUN
njb-229	46	3	of	of	ADP
njb-229	46	4	imipenem	imipenem	PROPN
njb-229	46	5	was	be	AUX
njb-229	46	6	interpreted	interpret	VERB
njb-229	46	7	and	and	CCONJ
njb-229	46	8	the	the	DET
njb-229	46	9	isolates	isolate	NOUN
njb-229	46	10	were	be	AUX
njb-229	46	11	differentiated	differentiate	VERB
njb-229	46	12	as	as	ADP
njb-229	46	13	sensitive	sensitive	ADJ
njb-229	46	14	(	(	PUNCT
njb-229	46	15	≤1	≤1	NUM
njb-229	46	16	µg	µg	PROPN
njb-229	46	17	/	/	SYM
njb-229	46	18	ml	ml	PROPN
njb-229	46	19	)	)	PUNCT
njb-229	46	20	,	,	PUNCT
njb-229	46	21	intermediate	intermediate	ADJ
njb-229	46	22	(	(	PUNCT
njb-229	46	23	2	2	NUM
njb-229	46	24	µg	µg	PROPN
njb-229	46	25	/	/	SYM
njb-229	46	26	ml	ml	PROPN
njb-229	46	27	)	)	PUNCT
njb-229	46	28	,	,	PUNCT
njb-229	46	29	and	and	CCONJ
njb-229	46	30	resistant	resistant	ADJ
njb-229	46	31	(	(	PUNCT
njb-229	46	32	≥4µg	≥4µg	NOUN
njb-229	46	33	/	/	SYM
njb-229	46	34	ml	ml	X
njb-229	46	35	)	)	PUNCT
njb-229	47	1	[	[	X
njb-229	47	2	15	15	NUM
njb-229	47	3	]	]	PUNCT
njb-229	47	4	.	.	PUNCT
njb-229	48	1	for	for	ADP
njb-229	48	2	quality	quality	NOUN
njb-229	48	3	control	control	NOUN
njb-229	48	4	of	of	ADP
njb-229	48	5	the	the	DET
njb-229	48	6	mic	mic	ADJ
njb-229	48	7	test	test	NOUN
njb-229	48	8	strip	strip	PROPN
njb-229	48	9	,	,	PUNCT
njb-229	48	10	carbapenem	carbapenem	PROPN
njb-229	48	11	susceptible	susceptible	ADJ
njb-229	48	12	escherichia	escherichia	NOUN
njb-229	48	13	coli	coli	NOUN
njb-229	48	14	atcc	atcc	NOUN
njb-229	48	15	25922	25922	NUM
njb-229	48	16	was	be	AUX
njb-229	48	17	used	use	VERB
njb-229	48	18	.	.	PUNCT
njb-229	49	1	results	result	VERB
njb-229	49	2	patient	patient	ADJ
njb-229	49	3	characterization	characterization	NOUN
njb-229	49	4	a	a	DET
njb-229	49	5	total	total	NOUN
njb-229	49	6	of	of	ADP
njb-229	49	7	3447	3447	NUM
njb-229	49	8	specimens	specimen	NOUN
njb-229	49	9	were	be	AUX
njb-229	49	10	received	receive	VERB
njb-229	49	11	in	in	ADP
njb-229	49	12	the	the	DET
njb-229	49	13	trimester	trimester	NOUN
njb-229	49	14	period	period	NOUN
njb-229	49	15	in	in	ADP
njb-229	49	16	which	which	PRON
njb-229	49	17	771	771	NUM
njb-229	49	18	samples	sample	NOUN
njb-229	49	19	showed	show	VERB
njb-229	49	20	culture	culture	NOUN
njb-229	49	21	-	-	PUNCT
njb-229	49	22	positive	positive	ADJ
njb-229	49	23	from	from	ADP
njb-229	49	24	which	which	PRON
njb-229	49	25	815	815	NUM
njb-229	49	26	bacteria	bacteria	NOUN
njb-229	49	27	were	be	AUX
njb-229	49	28	isolated	isolate	VERB
njb-229	49	29	.	.	PUNCT
njb-229	50	1	among	among	ADP
njb-229	50	2	815	815	NUM
njb-229	50	3	bacterial	bacterial	ADJ
njb-229	50	4	isolates	isolate	NOUN
njb-229	50	5	,	,	PUNCT
njb-229	50	6	85	85	NUM
njb-229	50	7	isolates	isolate	NOUN
njb-229	50	8	were	be	AUX
njb-229	50	9	confirmed	confirm	VERB
njb-229	50	10	as	as	ADP
njb-229	50	11	klebsiella	klebsiella	PROPN
njb-229	50	12	pneumoniae	pneumoniae	NOUN
njb-229	50	13	.	.	PUNCT
njb-229	51	1	the	the	DET
njb-229	51	2	rest	rest	NOUN
njb-229	51	3	data	datum	NOUN
njb-229	51	4	are	be	AUX
njb-229	51	5	shown	show	VERB
njb-229	51	6	in	in	ADP
njb-229	51	7	table	table	NOUN
njb-229	51	8	1	1	NUM
njb-229	51	9	.	.	PUNCT
njb-229	51	10	table	table	NOUN
njb-229	51	11	1	1	NUM
njb-229	51	12	.	.	PUNCT
njb-229	51	13	clinical	clinical	ADJ
njb-229	51	14	and	and	CCONJ
njb-229	51	15	social	social	ADJ
njb-229	51	16	demography	demography	NOUN
njb-229	51	17	of	of	ADP
njb-229	51	18	patients	patients	PROPN
njb-229	51	19	s.n	s.n	PROPN
njb-229	51	20	.	.	PROPN
njb-229	51	21	status	status	NOUN
njb-229	51	22	of	of	ADP
njb-229	51	23	patients	patient	NOUN
njb-229	51	24	number	number	NOUN
njb-229	51	25	(	(	PUNCT
njb-229	51	26	%	%	INTJ
njb-229	51	27	)	)	PUNCT
njb-229	51	28	1	1	NUM
njb-229	51	29	opd	opd	NOUN
njb-229	51	30	15	15	NUM
njb-229	51	31	(	(	PUNCT
njb-229	51	32	17.65	17.65	NUM
njb-229	51	33	%	%	NOUN
njb-229	51	34	)	)	PUNCT
njb-229	51	35	2	2	NUM
njb-229	51	36	inpatients	inpatient	NOUN
njb-229	51	37	70	70	NUM
njb-229	51	38	(	(	PUNCT
njb-229	51	39	82.35	82.35	NUM
njb-229	51	40	%	%	NOUN
njb-229	51	41	)	)	PUNCT
njb-229	51	42	s.n	s.n	PROPN
njb-229	51	43	.	.	PROPN
njb-229	51	44	sex	sex	NOUN
njb-229	51	45	number	number	NOUN
njb-229	51	46	1	1	NUM
njb-229	51	47	male	male	NOUN
njb-229	51	48	50	50	NUM
njb-229	51	49	(	(	PUNCT
njb-229	51	50	58.82	58.82	NUM
njb-229	51	51	%	%	NOUN
njb-229	51	52	)	)	PUNCT
njb-229	51	53	2	2	NUM
njb-229	51	54	female	female	ADJ
njb-229	51	55	35	35	NUM
njb-229	51	56	(	(	PUNCT
njb-229	51	57	41.18	41.18	NUM
njb-229	51	58	%	%	NOUN
njb-229	51	59	)	)	PUNCT
njb-229	51	60	s.n	s.n	PROPN
njb-229	51	61	.	.	PROPN
njb-229	51	62	age	age	NOUN
njb-229	51	63	group	group	NOUN
njb-229	51	64	number	number	NOUN
njb-229	51	65	1	1	NUM
njb-229	51	66	below	below	ADP
njb-229	51	67	20	20	NUM
njb-229	51	68	12	12	NUM
njb-229	51	69	(	(	PUNCT
njb-229	51	70	14.11	14.11	NUM
njb-229	51	71	%	%	NOUN
njb-229	51	72	)	)	PUNCT
njb-229	51	73	2	2	NUM
njb-229	51	74	20	20	NUM
njb-229	51	75	-	-	SYM
njb-229	51	76	30	30	NUM
njb-229	51	77	14	14	NUM
njb-229	51	78	(	(	PUNCT
njb-229	51	79	16.47	16.47	NUM
njb-229	51	80	%	%	NOUN
njb-229	51	81	)	)	PUNCT
njb-229	52	1	3	3	NUM
njb-229	52	2	30	30	NUM
njb-229	52	3	-	-	SYM
njb-229	52	4	40	40	NUM
njb-229	52	5	12	12	NUM
njb-229	52	6	(	(	PUNCT
njb-229	52	7	14.11	14.11	NUM
njb-229	52	8	%	%	NOUN
njb-229	52	9	)	)	PUNCT
njb-229	52	10	4	4	NUM
njb-229	52	11	40	40	NUM
njb-229	52	12	-	-	SYM
njb-229	52	13	50	50	NUM
njb-229	52	14	9	9	NUM
njb-229	52	15	(	(	PUNCT
njb-229	52	16	10.59	10.59	NUM
njb-229	52	17	%	%	NOUN
njb-229	52	18	)	)	PUNCT
njb-229	52	19	5	5	NUM
njb-229	52	20	50	50	NUM
njb-229	52	21	-	-	SYM
njb-229	52	22	60	60	NUM
njb-229	52	23	14	14	NUM
njb-229	52	24	(	(	PUNCT
njb-229	52	25	16.47	16.47	NUM
njb-229	52	26	%	%	NOUN
njb-229	52	27	)	)	PUNCT
njb-229	52	28	6	6	NUM
njb-229	52	29	60	60	NUM
njb-229	52	30	and	and	CCONJ
njb-229	52	31	above	above	ADP
njb-229	52	32	24	24	NUM
njb-229	52	33	(	(	PUNCT
njb-229	52	34	28.24	28.24	NUM
njb-229	52	35	%	%	NOUN
njb-229	52	36	)	)	PUNCT
njb-229	52	37	antibiotic	antibiotic	ADJ
njb-229	52	38	susceptibility	susceptibility	NOUN
njb-229	52	39	test	test	VERB
njb-229	52	40	the	the	DET
njb-229	52	41	antibiotic	antibiotic	ADJ
njb-229	52	42	susceptibility	susceptibility	NOUN
njb-229	52	43	test	test	NOUN
njb-229	52	44	showed	show	VERB
njb-229	52	45	that	that	SCONJ
njb-229	52	46	ceftriaxone	ceftriaxone	PROPN
njb-229	52	47	(	(	PUNCT
njb-229	52	48	59	59	NUM
njb-229	52	49	,	,	PUNCT
njb-229	52	50	69.42	69.42	NUM
njb-229	52	51	%	%	NOUN
njb-229	52	52	)	)	PUNCT
njb-229	52	53	was	be	AUX
njb-229	52	54	the	the	DET
njb-229	52	55	most	most	ADV
njb-229	52	56	non	non	ADJ
njb-229	52	57	-	-	ADJ
njb-229	52	58	susceptible	susceptible	ADJ
njb-229	52	59	antibiotic	antibiotic	ADJ
njb-229	52	60	,	,	PUNCT
njb-229	52	61	followed	follow	VERB
njb-229	52	62	by	by	ADP
njb-229	52	63	ciprofloxacin	ciprofloxacin	NOUN
njb-229	52	64	(	(	PUNCT
njb-229	52	65	49	49	NUM
njb-229	52	66	,	,	PUNCT
njb-229	52	67	57.65	57.65	NUM
njb-229	52	68	%	%	NOUN
njb-229	52	69	)	)	PUNCT
njb-229	52	70	and	and	CCONJ
njb-229	52	71	gentamicin	gentamicin	PROPN
njb-229	52	72	(	(	PUNCT
njb-229	52	73	48	48	NUM
njb-229	52	74	,	,	PUNCT
njb-229	52	75	56.47	56.47	NUM
njb-229	52	76	%	%	NOUN
njb-229	52	77	)	)	PUNCT
njb-229	52	78	.	.	PUNCT
njb-229	53	1	furthermore	furthermore	ADV
njb-229	53	2	,	,	PUNCT
njb-229	53	3	60	60	NUM
njb-229	53	4	%	%	NOUN
njb-229	53	5	(	(	PUNCT
njb-229	53	6	51	51	NUM
njb-229	53	7	of	of	ADP
njb-229	53	8	85	85	NUM
njb-229	53	9	)	)	PUNCT
njb-229	53	10	isolates	isolate	NOUN
njb-229	53	11	were	be	AUX
njb-229	53	12	multidrug	multidrug	NOUN
njb-229	53	13	-	-	PUNCT
njb-229	53	14	resistant	resistant	ADJ
njb-229	53	15	.	.	PUNCT
njb-229	54	1	the	the	DET
njb-229	54	2	remaining	remain	VERB
njb-229	54	3	data	datum	NOUN
njb-229	54	4	are	be	AUX
njb-229	54	5	shown	show	VERB
njb-229	54	6	in	in	ADP
njb-229	54	7	table	table	NOUN
njb-229	54	8	2	2	NUM
njb-229	54	9	.	.	PUNCT
njb-229	55	1	carbapenem	carbapenem	PROPN
njb-229	55	2	-	-	PUNCT
njb-229	55	3	resistant	resistant	ADJ
njb-229	55	4	the	the	DET
njb-229	55	5	screening	screening	NOUN
njb-229	55	6	of	of	ADP
njb-229	55	7	carbapenem	carbapenem	PROPN
njb-229	55	8	resistance	resistance	NOUN
njb-229	55	9	showed	show	VERB
njb-229	55	10	that	that	SCONJ
njb-229	55	11	in	in	ADP
njb-229	55	12	85	85	NUM
njb-229	55	13	k.	k.	NOUN
njb-229	55	14	pneumoniae	pneumoniae	NOUN
njb-229	55	15	isolates	isolate	NOUN
njb-229	55	16	,	,	PUNCT
njb-229	55	17	the	the	DET
njb-229	55	18	carbapenem	carbapenem	PROPN
njb-229	55	19	resistance	resistance	NOUN
njb-229	55	20	and	and	CCONJ
njb-229	55	21	intermediate	intermediate	ADJ
njb-229	55	22	isolates	isolate	NOUN
njb-229	55	23	were	be	AUX
njb-229	55	24	46	46	NUM
njb-229	55	25	(	(	PUNCT
njb-229	55	26	54.13	54.13	NUM
njb-229	55	27	%	%	NOUN
njb-229	55	28	)	)	PUNCT
njb-229	55	29	and	and	CCONJ
njb-229	55	30	three	three	NUM
njb-229	55	31	(	(	PUNCT
njb-229	55	32	3.52	3.52	NUM
njb-229	55	33	%	%	NOUN
njb-229	55	34	)	)	PUNCT
njb-229	55	35	respectively	respectively	ADV
njb-229	55	36	.	.	PUNCT
njb-229	56	1	the	the	DET
njb-229	56	2	mic	mic	ADJ
njb-229	56	3	test	test	NOUN
njb-229	56	4	of	of	ADP
njb-229	56	5	both	both	DET
njb-229	56	6	intermediate	intermediate	ADJ
njb-229	56	7	and	and	CCONJ
njb-229	56	8	resistant	resistant	ADJ
njb-229	56	9	isolates	isolate	NOUN
njb-229	56	10	was	be	AUX
njb-229	56	11	done	do	VERB
njb-229	56	12	as	as	SCONJ
njb-229	56	13	suggested	suggest	VERB
njb-229	56	14	by	by	ADP
njb-229	56	15	the	the	DET
njb-229	56	16	clsi	clsi	NOUN
njb-229	56	17	guideline	guideline	NOUN
njb-229	56	18	2018	2018	NUM
njb-229	56	19	.	.	PUNCT
njb-229	57	1	among	among	ADP
njb-229	57	2	the	the	DET
njb-229	57	3	49	49	NUM
njb-229	57	4	isolates	isolate	NOUN
njb-229	57	5	,	,	PUNCT
njb-229	57	6	the	the	DET
njb-229	57	7	mic	mic	ADJ
njb-229	57	8	test	test	NOUN
njb-229	57	9	of	of	ADP
njb-229	57	10	imipenem	imipenem	PROPN
njb-229	57	11	showed	show	VERB
njb-229	57	12	that	that	SCONJ
njb-229	57	13	31	31	NUM
njb-229	57	14	isolates	isolate	NOUN
njb-229	57	15	were	be	AUX
njb-229	57	16	resistant	resistant	ADJ
njb-229	57	17	,	,	PUNCT
njb-229	57	18	five	five	NUM
njb-229	57	19	intermediate	intermediate	ADJ
njb-229	57	20	,	,	PUNCT
njb-229	57	21	and	and	CCONJ
njb-229	57	22	13	13	NUM
njb-229	57	23	sensitives	sensitive	NOUN
njb-229	57	24	.	.	PUNCT
njb-229	58	1	furthermore	furthermore	ADV
njb-229	58	2	,	,	PUNCT
njb-229	58	3	in	in	ADP
njb-229	58	4	85	85	NUM
njb-229	58	5	isolates	isolate	NOUN
njb-229	58	6	,	,	PUNCT
njb-229	58	7	51	51	NUM
njb-229	58	8	isolates	isolate	NOUN
njb-229	58	9	were	be	AUX
njb-229	58	10	mdr	mdr	PROPN
njb-229	58	11	k.	k.	PROPN
njb-229	58	12	pneumoniae	pneumoniae	NOUN
njb-229	58	13	isolates	isolate	NOUN
njb-229	58	14	,	,	PUNCT
njb-229	58	15	in	in	ADP
njb-229	58	16	which	which	PRON
njb-229	58	17	45	45	NUM
njb-229	58	18	isolates	isolate	NOUN
njb-229	58	19	were	be	AUX
njb-229	58	20	resistant	resistant	ADJ
njb-229	58	21	to	to	ADP
njb-229	58	22	carbapenem	carbapenem	PROPN
njb-229	58	23	and	and	CCONJ
njb-229	58	24	six	six	NUM
njb-229	58	25	isolates	isolate	NOUN
njb-229	58	26	were	be	AUX
njb-229	58	27	susceptible	susceptible	ADJ
njb-229	58	28	to	to	ADP
njb-229	58	29	carbapenem	carbapenem	PROPN
njb-229	58	30	.	.	PROPN
njb-229	58	31	nepal	nepal	PROPN
njb-229	58	32	j	j	PROPN
njb-229	58	33	biotechnol	biotechnol	PROPN
njb-229	58	34	.	.	PUNCT
njb-229	59	1	2	2	NUM
njb-229	59	2	0	0	NUM
njb-229	59	3	2	2	NUM
njb-229	59	4	2	2	NUM
njb-229	59	5	j	j	NOUN
njb-229	59	6	u	u	NOUN
njb-229	59	7	l	l	NOUN
njb-229	59	8	;	;	PUNCT
njb-229	59	9	1	1	NUM
njb-229	59	10	0	0	NUM
njb-229	59	11	(	(	PUNCT
njb-229	59	12	1):4	1):4	NUM
njb-229	59	13	0	0	NUM
njb-229	59	14	4	4	NUM
njb-229	59	15	4	4	NUM
njb-229	59	16	saud	saud	PROPN
njb-229	59	17	et	et	PROPN
njb-229	59	18	al	al	PROPN
njb-229	59	19	.	.	PUNCT
njb-229	60	1	©	©	PROPN
njb-229	60	2	njb	njb	PROPN
njb-229	60	3	,	,	PUNCT
njb-229	60	4	bsn	bsn	PROPN
njb-229	60	5	42	42	NUM
njb-229	60	6	figure	figure	NOUN
njb-229	60	7	1	1	NUM
njb-229	60	8	.	.	PUNCT
njb-229	61	1	mic	mic	ADJ
njb-229	61	2	test	test	NOUN
njb-229	61	3	discussion	discussion	PROPN
njb-229	61	4	klebsiella	klebsiella	PROPN
njb-229	61	5	pneumoniae	pneumoniae	NOUN
njb-229	61	6	is	be	AUX
njb-229	61	7	an	an	DET
njb-229	61	8	opportunistic	opportunistic	ADJ
njb-229	61	9	pathogen	pathogen	NOUN
njb-229	61	10	responsible	responsible	ADJ
njb-229	61	11	for	for	ADP
njb-229	61	12	causing	cause	VERB
njb-229	61	13	various	various	ADJ
njb-229	61	14	community	community	NOUN
njb-229	61	15	-	-	PUNCT
njb-229	61	16	acquired	acquire	VERB
njb-229	61	17	and	and	CCONJ
njb-229	61	18	healthcare	healthcare	NOUN
njb-229	61	19	-	-	PUNCT
njb-229	61	20	associated	associate	VERB
njb-229	61	21	infections	infection	NOUN
njb-229	61	22	.	.	PUNCT
njb-229	62	1	furthermore	furthermore	ADV
njb-229	62	2	,	,	PUNCT
njb-229	62	3	the	the	DET
njb-229	62	4	infection	infection	NOUN
njb-229	62	5	caused	cause	VERB
njb-229	62	6	by	by	ADP
njb-229	62	7	this	this	DET
njb-229	62	8	bacterium	bacterium	NOUN
njb-229	62	9	can	can	AUX
njb-229	62	10	not	not	PART
njb-229	62	11	be	be	AUX
njb-229	62	12	neglected	neglect	VERB
njb-229	62	13	,	,	PUNCT
njb-229	62	14	as	as	SCONJ
njb-229	62	15	it	it	PRON
njb-229	62	16	is	be	AUX
njb-229	62	17	included	include	VERB
njb-229	62	18	in	in	ADP
njb-229	62	19	eskape	eskape	NOUN
njb-229	62	20	pathogens	pathogen	NOUN
njb-229	62	21	and	and	CCONJ
njb-229	62	22	the	the	DET
njb-229	62	23	increasing	increase	VERB
njb-229	62	24	incidence	incidence	NOUN
njb-229	62	25	of	of	ADP
njb-229	62	26	crkp	crkp	NOUN
njb-229	62	27	strains	strain	VERB
njb-229	62	28	attracts	attract	VERB
njb-229	62	29	attention	attention	NOUN
njb-229	62	30	to	to	ADP
njb-229	62	31	clinicians	clinician	NOUN
njb-229	62	32	and	and	CCONJ
njb-229	62	33	other	other	ADJ
njb-229	62	34	stakeholders	stakeholder	NOUN
njb-229	62	35	.	.	PUNCT
njb-229	63	1	in	in	ADP
njb-229	63	2	our	our	PRON
njb-229	63	3	study	study	NOUN
njb-229	63	4	,	,	PUNCT
njb-229	63	5	the	the	DET
njb-229	63	6	highest	high	ADJ
njb-229	63	7	percentage	percentage	NOUN
njb-229	63	8	of	of	ADP
njb-229	63	9	k.	k.	NOUN
njb-229	63	10	pneumoniae	pneumoniae	NOUN
njb-229	63	11	was	be	AUX
njb-229	63	12	obtained	obtain	VERB
njb-229	63	13	in	in	ADP
njb-229	63	14	the	the	DET
njb-229	63	15	inpatient	inpatient	NOUN
njb-229	63	16	department	department	NOUN
njb-229	63	17	than	than	ADP
njb-229	63	18	others	other	NOUN
njb-229	63	19	.	.	PUNCT
njb-229	64	1	this	this	DET
njb-229	64	2	higher	high	ADJ
njb-229	64	3	incidence	incidence	NOUN
njb-229	64	4	of	of	ADP
njb-229	64	5	k.	k.	NOUN
njb-229	64	6	pneumoniae	pneumoniae	NOUN
njb-229	64	7	in	in	ADP
njb-229	64	8	long	long	ADJ
njb-229	64	9	-	-	PUNCT
njb-229	64	10	term	term	NOUN
njb-229	64	11	hospitalized	hospitalize	VERB
njb-229	64	12	patients	patient	NOUN
njb-229	64	13	may	may	AUX
njb-229	64	14	be	be	AUX
njb-229	64	15	related	relate	VERB
njb-229	64	16	to	to	ADP
njb-229	64	17	the	the	DET
njb-229	64	18	immune	immune	ADJ
njb-229	64	19	status	status	NOUN
njb-229	64	20	of	of	ADP
njb-229	64	21	the	the	DET
njb-229	64	22	patients	patient	NOUN
njb-229	64	23	,	,	PUNCT
njb-229	64	24	as	as	SCONJ
njb-229	64	25	the	the	DET
njb-229	64	26	bacterium	bacterium	NOUN
njb-229	64	27	was	be	AUX
njb-229	64	28	isolated	isolate	VERB
njb-229	64	29	from	from	ADP
njb-229	64	30	the	the	DET
njb-229	64	31	surgery	surgery	NOUN
njb-229	64	32	unit	unit	NOUN
njb-229	64	33	with	with	ADP
njb-229	64	34	the	the	DET
njb-229	64	35	use	use	NOUN
njb-229	64	36	of	of	ADP
njb-229	64	37	invasive	invasive	ADJ
njb-229	64	38	devices	device	NOUN
njb-229	64	39	and	and	CCONJ
njb-229	64	40	administration	administration	NOUN
njb-229	64	41	of	of	ADP
njb-229	64	42	immunosuppressive	immunosuppressive	ADJ
njb-229	64	43	drugs	drug	NOUN
njb-229	64	44	.	.	PUNCT
njb-229	65	1	in	in	ADP
njb-229	65	2	hospital	hospital	NOUN
njb-229	65	3	settings	setting	NOUN
njb-229	65	4	,	,	PUNCT
njb-229	65	5	the	the	DET
njb-229	65	6	transmission	transmission	NOUN
njb-229	65	7	of	of	ADP
njb-229	65	8	the	the	DET
njb-229	65	9	pathogen	pathogen	PROPN
njb-229	65	10	increases	increase	VERB
njb-229	65	11	drastically	drastically	ADV
njb-229	65	12	because	because	SCONJ
njb-229	65	13	the	the	DET
njb-229	65	14	colonization	colonization	NOUN
njb-229	65	15	rate	rate	NOUN
njb-229	65	16	increases	increase	VERB
njb-229	65	17	with	with	ADP
njb-229	65	18	an	an	DET
njb-229	65	19	extended	extended	ADJ
njb-229	65	20	stay	stay	NOUN
njb-229	65	21	in	in	ADP
njb-229	65	22	the	the	DET
njb-229	65	23	hospital	hospital	NOUN
njb-229	65	24	and	and	CCONJ
njb-229	65	25	prolonged	prolong	VERB
njb-229	65	26	antibiotic	antibiotic	ADJ
njb-229	65	27	therapy	therapy	NOUN
njb-229	65	28	.	.	PUNCT
njb-229	66	1	a	a	DET
njb-229	66	2	similar	similar	ADJ
njb-229	66	3	study	study	NOUN
njb-229	66	4	carried	carry	VERB
njb-229	66	5	out	out	ADP
njb-229	66	6	in	in	ADP
njb-229	66	7	the	the	DET
njb-229	66	8	united	united	PROPN
njb-229	66	9	states	states	PROPN
njb-229	66	10	also	also	ADV
njb-229	66	11	claimed	claim	VERB
njb-229	66	12	a	a	DET
njb-229	66	13	higher	high	ADJ
njb-229	66	14	incidence	incidence	NOUN
njb-229	66	15	of	of	ADP
njb-229	66	16	k.	k.	NOUN
njb-229	66	17	pneumoniae	pneumoniae	NOUN
njb-229	66	18	infections	infection	NOUN
njb-229	66	19	in	in	ADP
njb-229	66	20	long	long	ADJ
njb-229	66	21	-	-	PUNCT
njb-229	66	22	term	term	NOUN
njb-229	66	23	acute	acute	ADJ
njb-229	66	24	care	care	NOUN
njb-229	66	25	hospitals	hospital	NOUN
njb-229	66	26	than	than	ADP
njb-229	66	27	in	in	ADP
njb-229	66	28	the	the	DET
njb-229	66	29	short	short	ADJ
njb-229	66	30	-	-	PUNCT
njb-229	66	31	term	term	NOUN
njb-229	66	32	hospital	hospital	NOUN
njb-229	66	33	stay	stay	VERB
njb-229	66	34	[	[	X
njb-229	66	35	16	16	NUM
njb-229	66	36	]	]	PUNCT
njb-229	66	37	.	.	PUNCT
njb-229	67	1	antibiotic	antibiotic	ADJ
njb-229	67	2	resistance	resistance	NOUN
njb-229	67	3	is	be	AUX
njb-229	67	4	a	a	DET
njb-229	67	5	common	common	ADJ
njb-229	67	6	problem	problem	NOUN
njb-229	67	7	in	in	ADP
njb-229	67	8	k.	k.	NOUN
njb-229	67	9	pneumoniae	pneumoniae	NOUN
njb-229	67	10	.	.	PUNCT
njb-229	68	1	it	it	PRON
njb-229	68	2	is	be	AUX
njb-229	68	3	naturally	naturally	ADV
njb-229	68	4	resistant	resistant	ADJ
njb-229	68	5	to	to	ADP
njb-229	68	6	the	the	DET
njb-229	68	7	penicillin	penicillin	NOUN
njb-229	68	8	group	group	NOUN
njb-229	68	9	of	of	ADP
njb-229	68	10	antibiotics	antibiotic	NOUN
njb-229	68	11	[	[	PUNCT
njb-229	68	12	17	17	NUM
njb-229	68	13	]	]	PUNCT
njb-229	68	14	or	or	CCONJ
njb-229	68	15	acquires	acquire	VERB
njb-229	68	16	antibiotic	antibiotic	ADJ
njb-229	68	17	resistance	resistance	NOUN
njb-229	68	18	genes	gene	NOUN
njb-229	68	19	from	from	ADP
njb-229	68	20	mobile	mobile	ADJ
njb-229	68	21	genetic	genetic	ADJ
njb-229	68	22	cassettes	cassette	NOUN
njb-229	68	23	called	call	VERB
njb-229	68	24	integrons	integron	NOUN
njb-229	68	25	,	,	PUNCT
njb-229	68	26	often	often	ADV
njb-229	68	27	carried	carry	VERB
njb-229	68	28	out	out	ADP
njb-229	68	29	by	by	ADP
njb-229	68	30	transposons	transposon	NOUN
njb-229	68	31	and	and	CCONJ
njb-229	68	32	transferable	transferable	ADJ
njb-229	68	33	plasmids	plasmid	NOUN
njb-229	68	34	that	that	PRON
njb-229	68	35	transmit	transmit	VERB
njb-229	68	36	horizontally	horizontally	ADV
njb-229	68	37	to	to	ADP
njb-229	68	38	receptor	receptor	NOUN
njb-229	68	39	cells	cell	NOUN
njb-229	68	40	,	,	PUNCT
njb-229	68	41	integrated	integrate	VERB
njb-229	68	42	on	on	ADP
njb-229	68	43	plasmids	plasmid	NOUN
njb-229	68	44	or	or	CCONJ
njb-229	68	45	chromosomes	chromosome	NOUN
njb-229	68	46	through	through	ADP
njb-229	68	47	homologous	homologous	ADJ
njb-229	68	48	recombination	recombination	NOUN
njb-229	68	49	,	,	PUNCT
njb-229	68	50	expressing	express	VERB
njb-229	68	51	its	its	PRON
njb-229	68	52	fitness	fitness	NOUN
njb-229	68	53	in	in	ADP
njb-229	68	54	the	the	DET
njb-229	68	55	presence	presence	NOUN
njb-229	68	56	of	of	ADP
njb-229	68	57	antibiotics	antibiotic	NOUN
njb-229	68	58	[	[	PUNCT
njb-229	68	59	18	18	NUM
njb-229	68	60	]	]	PUNCT
njb-229	68	61	.	.	PUNCT
njb-229	69	1	in	in	ADP
njb-229	69	2	this	this	DET
njb-229	69	3	study	study	NOUN
njb-229	69	4	,	,	PUNCT
njb-229	69	5	we	we	PRON
njb-229	69	6	evaluated	evaluate	VERB
njb-229	69	7	11	11	NUM
njb-229	69	8	different	different	ADJ
njb-229	69	9	antibiotics	antibiotic	NOUN
njb-229	69	10	,	,	PUNCT
njb-229	69	11	in	in	ADP
njb-229	69	12	which	which	PRON
njb-229	69	13	amikacin	amikacin	PROPN
njb-229	69	14	,	,	PUNCT
njb-229	69	15	gentamicin	gentamicin	PROPN
njb-229	69	16	,	,	PUNCT
njb-229	69	17	ciprofloxacin	ciprofloxacin	NOUN
njb-229	69	18	,	,	PUNCT
njb-229	69	19	ofloxacin	ofloxacin	NOUN
njb-229	69	20	,	,	PUNCT
njb-229	69	21	ceftriaxone	ceftriaxone	PROPN
njb-229	69	22	,	,	PUNCT
njb-229	69	23	ertapenem	ertapenem	PROPN
njb-229	69	24	were	be	AUX
njb-229	69	25	tested	test	VERB
njb-229	69	26	in	in	ADP
njb-229	69	27	all	all	DET
njb-229	69	28	isolates	isolate	NOUN
njb-229	69	29	,	,	PUNCT
njb-229	69	30	and	and	CCONJ
njb-229	69	31	the	the	DET
njb-229	69	32	rest	rest	NOUN
njb-229	69	33	antibiotics	antibiotic	NOUN
njb-229	69	34	were	be	AUX
njb-229	69	35	tested	test	VERB
njb-229	69	36	either	either	CCONJ
njb-229	69	37	as	as	ADP
njb-229	69	38	second	second	ADJ
njb-229	69	39	-	-	PUNCT
njb-229	69	40	line	line	NOUN
njb-229	69	41	antibiotics	antibiotic	NOUN
njb-229	69	42	or	or	CCONJ
njb-229	69	43	depending	depend	VERB
njb-229	69	44	on	on	ADP
njb-229	69	45	a	a	DET
njb-229	69	46	source	source	NOUN
njb-229	69	47	of	of	ADP
njb-229	69	48	clinical	clinical	ADJ
njb-229	69	49	samples	sample	NOUN
njb-229	69	50	.	.	PUNCT
njb-229	70	1	our	our	PRON
njb-229	70	2	results	result	NOUN
njb-229	70	3	showed	show	VERB
njb-229	70	4	a	a	DET
njb-229	70	5	mixed	mixed	ADJ
njb-229	70	6	antibiotic	antibiotic	ADJ
njb-229	70	7	resistance	resistance	NOUN
njb-229	70	8	profile	profile	NOUN
njb-229	70	9	compared	compare	VERB
njb-229	70	10	to	to	ADP
njb-229	70	11	others	other	NOUN
njb-229	70	12	in	in	ADP
njb-229	70	13	terms	term	NOUN
njb-229	70	14	of	of	ADP
njb-229	70	15	antibiotic	antibiotic	ADJ
njb-229	70	16	use	use	NOUN
njb-229	70	17	,	,	PUNCT
njb-229	70	18	time	time	NOUN
njb-229	70	19	period	period	NOUN
njb-229	70	20	,	,	PUNCT
njb-229	70	21	bacterium	bacterium	NOUN
njb-229	70	22	source	source	NOUN
njb-229	70	23	and	and	CCONJ
njb-229	70	24	country	country	NOUN
njb-229	70	25	.	.	PUNCT
njb-229	71	1	approximately	approximately	ADV
njb-229	71	2	48.24	48.24	NUM
njb-229	71	3	%	%	NOUN
njb-229	71	4	and	and	CCONJ
njb-229	71	5	56.47	56.47	NUM
njb-229	71	6	%	%	NOUN
njb-229	71	7	of	of	ADP
njb-229	71	8	the	the	DET
njb-229	71	9	isolates	isolate	NOUN
njb-229	71	10	were	be	AUX
njb-229	71	11	not	not	PART
njb-229	71	12	susceptible	susceptible	ADJ
njb-229	71	13	to	to	ADP
njb-229	71	14	aminoglycosides	aminoglycoside	NOUN
njb-229	71	15	,	,	PUNCT
njb-229	71	16	amikacin	amikacin	PROPN
njb-229	71	17	,	,	PUNCT
njb-229	71	18	and	and	CCONJ
njb-229	71	19	gentamicin	gentamicin	PROPN
njb-229	71	20	,	,	PUNCT
njb-229	71	21	respectively	respectively	ADV
njb-229	71	22	.	.	PUNCT
njb-229	72	1	a	a	DET
njb-229	72	2	range	range	NOUN
njb-229	72	3	of	of	ADP
njb-229	72	4	studies	study	NOUN
njb-229	72	5	shows	show	VERB
njb-229	72	6	a	a	DET
njb-229	72	7	wide	wide	ADJ
njb-229	72	8	variation	variation	NOUN
njb-229	72	9	in	in	ADP
njb-229	72	10	resistance	resistance	NOUN
njb-229	72	11	pictures	picture	NOUN
njb-229	72	12	that	that	PRON
njb-229	72	13	range	range	VERB
njb-229	72	14	from	from	ADP
njb-229	72	15	1	1	NUM
njb-229	72	16	%	%	NOUN
njb-229	72	17	to	to	PART
njb-229	72	18	86	86	NUM
njb-229	72	19	%	%	NOUN
njb-229	72	20	for	for	ADP
njb-229	72	21	gentamicin	gentamicin	PROPN
njb-229	72	22	.	.	PUNCT
njb-229	73	1	a	a	DET
njb-229	73	2	study	study	NOUN
njb-229	73	3	in	in	ADP
njb-229	73	4	the	the	DET
njb-229	73	5	eu	eu	PROPN
njb-229	73	6	/	/	SYM
njb-229	73	7	eea	eea	PROPN
njb-229	73	8	region	region	NOUN
njb-229	73	9	showed	show	VERB
njb-229	73	10	that	that	SCONJ
njb-229	73	11	its	its	PRON
njb-229	73	12	resistance	resistance	NOUN
njb-229	73	13	per	per	ADP
njb-229	73	14	cent	cent	NOUN
njb-229	73	15	ranges	range	VERB
njb-229	73	16	from	from	ADP
njb-229	73	17	below	below	ADP
njb-229	73	18	1	1	NUM
njb-229	73	19	%	%	NOUN
njb-229	73	20	to	to	ADP
njb-229	73	21	greater	great	ADJ
njb-229	73	22	than	than	ADP
njb-229	73	23	50	50	NUM
njb-229	73	24	[	[	PUNCT
njb-229	73	25	19	19	NUM
njb-229	73	26	]	]	PUNCT
njb-229	73	27	.	.	PUNCT
njb-229	74	1	a	a	DET
njb-229	74	2	comparative	comparative	ADJ
njb-229	74	3	study	study	NOUN
njb-229	74	4	from	from	ADP
njb-229	74	5	france	france	PROPN
njb-229	74	6	and	and	CCONJ
njb-229	74	7	algeria	algeria	PROPN
njb-229	74	8	revealed	reveal	VERB
njb-229	74	9	that	that	SCONJ
njb-229	74	10	its	its	PRON
njb-229	74	11	resistance	resistance	NOUN
njb-229	74	12	was	be	AUX
njb-229	74	13	28	28	NUM
njb-229	74	14	%	%	NOUN
njb-229	74	15	and	and	CCONJ
njb-229	74	16	86	86	NUM
njb-229	74	17	%	%	NOUN
njb-229	74	18	,	,	PUNCT
njb-229	74	19	respectively	respectively	ADV
njb-229	74	20	,	,	PUNCT
njb-229	74	21	[	[	X
njb-229	74	22	20	20	NUM
njb-229	74	23	]	]	PUNCT
njb-229	74	24	while	while	SCONJ
njb-229	74	25	in	in	ADP
njb-229	74	26	a	a	DET
njb-229	74	27	study	study	NOUN
njb-229	74	28	from	from	ADP
njb-229	74	29	iran	iran	PROPN
njb-229	74	30	and	and	CCONJ
njb-229	74	31	india	india	PROPN
njb-229	74	32	,	,	PUNCT
njb-229	74	33	the	the	DET
njb-229	74	34	resistance	resistance	NOUN
njb-229	74	35	rate	rate	NOUN
njb-229	74	36	was	be	AUX
njb-229	74	37	found	find	VERB
njb-229	74	38	to	to	PART
njb-229	74	39	be	be	AUX
njb-229	74	40	24	24	NUM
njb-229	74	41	%	%	NOUN
njb-229	74	42	and	and	CCONJ
njb-229	74	43	37.5	37.5	NUM
njb-229	74	44	%	%	NOUN
njb-229	74	45	,	,	PUNCT
njb-229	74	46	respectively	respectively	ADV
njb-229	74	47	[	[	X
njb-229	74	48	21	21	NUM
njb-229	74	49	,	,	PUNCT
njb-229	74	50	22	22	NUM
njb-229	74	51	]	]	PUNCT
njb-229	74	52	.	.	PUNCT
njb-229	75	1	a	a	DET
njb-229	75	2	slightly	slightly	ADV
njb-229	75	3	lower	low	ADJ
njb-229	75	4	percentage	percentage	NOUN
njb-229	75	5	,	,	PUNCT
njb-229	75	6	41	41	NUM
njb-229	75	7	%	%	NOUN
njb-229	75	8	,	,	PUNCT
njb-229	75	9	was	be	AUX
njb-229	75	10	observed	observe	VERB
njb-229	75	11	in	in	ADP
njb-229	75	12	nepal	nepal	ADJ
njb-229	75	13	[	[	PUNCT
njb-229	75	14	23	23	NUM
njb-229	75	15	]	]	PUNCT
njb-229	75	16	which	which	PRON
njb-229	75	17	is	be	AUX
njb-229	75	18	nearly	nearly	ADV
njb-229	75	19	equal	equal	ADJ
njb-229	75	20	to	to	ADP
njb-229	75	21	our	our	PRON
njb-229	75	22	study	study	NOUN
njb-229	75	23	.	.	PUNCT
njb-229	76	1	cephalosporins	cephalosporin	NOUN
njb-229	76	2	,	,	PUNCT
njb-229	76	3	such	such	ADJ
njb-229	76	4	as	as	ADP
njb-229	76	5	ceftriaxone	ceftriaxone	PROPN
njb-229	76	6	,	,	PUNCT
njb-229	76	7	are	be	AUX
njb-229	76	8	frequently	frequently	ADV
njb-229	76	9	used	use	VERB
njb-229	76	10	antibiotics	antibiotic	NOUN
njb-229	76	11	for	for	ADP
njb-229	76	12	k.	k.	NOUN
njb-229	76	13	pneumoniae	pneumoniae	NOUN
njb-229	76	14	until	until	SCONJ
njb-229	76	15	they	they	PRON
njb-229	76	16	become	become	VERB
njb-229	76	17	esbl	esbl	PROPN
njb-229	76	18	producers	producer	NOUN
njb-229	76	19	.	.	PUNCT
njb-229	77	1	our	our	PRON
njb-229	77	2	study	study	NOUN
njb-229	77	3	showed	show	VERB
njb-229	77	4	that	that	SCONJ
njb-229	77	5	nearly	nearly	ADV
njb-229	77	6	70	70	NUM
njb-229	77	7	%	%	NOUN
njb-229	77	8	of	of	ADP
njb-229	77	9	the	the	DET
njb-229	77	10	isolates	isolate	NOUN
njb-229	77	11	were	be	AUX
njb-229	77	12	resistant	resistant	ADJ
njb-229	77	13	to	to	ADP
njb-229	77	14	ceftriaxone	ceftriaxone	PROPN
njb-229	77	15	.	.	PUNCT
njb-229	78	1	a	a	DET
njb-229	78	2	similar	similar	ADJ
njb-229	78	3	finding	finding	NOUN
njb-229	78	4	was	be	AUX
njb-229	78	5	described	describe	VERB
njb-229	78	6	from	from	ADP
njb-229	78	7	ethiopia	ethiopia	PROPN
njb-229	79	1	[	[	PUNCT
njb-229	79	2	24	24	NUM
njb-229	79	3	]	]	PUNCT
njb-229	79	4	and	and	CCONJ
njb-229	79	5	a	a	DET
njb-229	79	6	four	four	NUM
njb-229	79	7	-	-	PUNCT
njb-229	79	8	year	year	NOUN
njb-229	79	9	consecutive	consecutive	ADJ
njb-229	79	10	study	study	NOUN
njb-229	79	11	from	from	ADP
njb-229	79	12	greece	greece	PROPN
njb-229	80	1	[	[	PUNCT
njb-229	80	2	19	19	NUM
njb-229	80	3	]	]	PUNCT
njb-229	80	4	.	.	PUNCT
njb-229	81	1	ciprofloxacin	ciprofloxacin	NOUN
njb-229	81	2	and	and	CCONJ
njb-229	81	3	table	table	NOUN
njb-229	81	4	2	2	NUM
njb-229	81	5	.	.	PUNCT
njb-229	82	1	antibiotic	antibiotic	ADJ
njb-229	82	2	susceptibility	susceptibility	NOUN
njb-229	82	3	pattern	pattern	NOUN
njb-229	82	4	of	of	ADP
njb-229	82	5	k.	k.	PROPN
njb-229	82	6	pneumoniae	pneumoniae	PROPN
njb-229	82	7	s.n	s.n	PROPN
njb-229	82	8	.	.	PROPN
njb-229	82	9	antibiotic	antibiotic	ADJ
njb-229	82	10	susceptibility	susceptibility	NOUN
njb-229	82	11	pattern	pattern	NOUN
njb-229	82	12	total	total	NOUN
njb-229	82	13	isolates	isolate	NOUN
njb-229	82	14	antibiotics	antibiotic	NOUN
njb-229	82	15	used	use	VERB
njb-229	82	16	sensitive	sensitive	ADJ
njb-229	82	17	(	(	PUNCT
njb-229	82	18	%	%	INTJ
njb-229	82	19	)	)	PUNCT
njb-229	82	20	intermediate	intermediate	ADJ
njb-229	82	21	(	(	PUNCT
njb-229	82	22	%	%	INTJ
njb-229	82	23	)	)	PUNCT
njb-229	82	24	resistant	resistant	ADJ
njb-229	82	25	(	(	PUNCT
njb-229	82	26	%	%	INTJ
njb-229	82	27	)	)	PUNCT
njb-229	82	28	1	1	NUM
njb-229	82	29	amikacin	amikacin	PROPN
njb-229	82	30	24	24	NUM
njb-229	82	31	(	(	PUNCT
njb-229	82	32	28.23	28.23	NUM
njb-229	82	33	)	)	PUNCT
njb-229	82	34	20	20	NUM
njb-229	82	35	(	(	PUNCT
njb-229	82	36	23.53	23.53	NUM
njb-229	82	37	)	)	PUNCT
njb-229	82	38	41	41	NUM
njb-229	82	39	(	(	PUNCT
njb-229	82	40	48.24	48.24	NUM
njb-229	82	41	)	)	PUNCT
njb-229	82	42	85	85	NUM
njb-229	82	43	2	2	NUM
njb-229	82	44	gentamicin	gentamicin	NOUN
njb-229	82	45	34	34	NUM
njb-229	82	46	(	(	PUNCT
njb-229	82	47	40	40	NUM
njb-229	82	48	)	)	PUNCT
njb-229	82	49	3	3	NUM
njb-229	82	50	(	(	PUNCT
njb-229	82	51	3.53	3.53	NUM
njb-229	82	52	)	)	PUNCT
njb-229	82	53	48	48	NUM
njb-229	82	54	(	(	PUNCT
njb-229	82	55	56.47	56.47	NUM
njb-229	82	56	)	)	PUNCT
njb-229	82	57	85	85	NUM
njb-229	82	58	3	3	NUM
njb-229	82	59	ciprofloxacin	ciprofloxacin	NOUN
njb-229	82	60	28	28	NUM
njb-229	82	61	(	(	PUNCT
njb-229	82	62	32.94	32.94	NUM
njb-229	82	63	)	)	PUNCT
njb-229	82	64	8	8	NUM
njb-229	82	65	(	(	PUNCT
njb-229	82	66	9.41	9.41	NUM
njb-229	82	67	)	)	PUNCT
njb-229	82	68	49	49	NUM
njb-229	82	69	(	(	PUNCT
njb-229	82	70	57.65	57.65	NUM
njb-229	82	71	)	)	PUNCT
njb-229	82	72	85	85	NUM
njb-229	82	73	4	4	NUM
njb-229	82	74	ofloxacin	ofloxacin	NOUN
njb-229	82	75	33	33	NUM
njb-229	82	76	(	(	PUNCT
njb-229	82	77	38.82	38.82	NUM
njb-229	82	78	)	)	PUNCT
njb-229	82	79	5	5	NUM
njb-229	82	80	(	(	PUNCT
njb-229	82	81	5.88	5.88	NUM
njb-229	82	82	)	)	PUNCT
njb-229	82	83	47	47	NUM
njb-229	82	84	(	(	PUNCT
njb-229	82	85	55.30	55.30	NUM
njb-229	82	86	)	)	PUNCT
njb-229	82	87	85	85	NUM
njb-229	82	88	5	5	NUM
njb-229	82	89	ceftriaxone	ceftriaxone	PROPN
njb-229	82	90	24	24	NUM
njb-229	82	91	(	(	PUNCT
njb-229	82	92	28.23	28.23	NUM
njb-229	82	93	)	)	PUNCT
njb-229	82	94	2	2	NUM
njb-229	82	95	(	(	PUNCT
njb-229	82	96	2.35	2.35	NUM
njb-229	82	97	)	)	PUNCT
njb-229	82	98	59	59	NUM
njb-229	82	99	(	(	PUNCT
njb-229	82	100	69.42	69.42	NUM
njb-229	82	101	)	)	PUNCT
njb-229	82	102	85	85	NUM
njb-229	82	103	6	6	NUM
njb-229	82	104	ertapenem	ertapenem	PROPN
njb-229	82	105	36	36	NUM
njb-229	82	106	(	(	PUNCT
njb-229	82	107	42.35	42.35	NUM
njb-229	82	108	)	)	PUNCT
njb-229	82	109	3	3	NUM
njb-229	82	110	(	(	PUNCT
njb-229	82	111	3.52	3.52	NUM
njb-229	82	112	)	)	PUNCT
njb-229	82	113	46	46	NUM
njb-229	82	114	(	(	PUNCT
njb-229	82	115	54.13	54.13	NUM
njb-229	82	116	)	)	PUNCT
njb-229	82	117	85	85	NUM
njb-229	82	118	7	7	NUM
njb-229	82	119	cefepime	cefepime	ADV
njb-229	82	120	11	11	NUM
njb-229	82	121	(	(	PUNCT
njb-229	82	122	16.18	16.18	NUM
njb-229	82	123	)	)	PUNCT
njb-229	82	124	8	8	NUM
njb-229	82	125	(	(	PUNCT
njb-229	82	126	11.76	11.76	NUM
njb-229	82	127	)	)	PUNCT
njb-229	82	128	49	49	NUM
njb-229	82	129	(	(	PUNCT
njb-229	82	130	72.06	72.06	NUM
njb-229	82	131	)	)	PUNCT
njb-229	82	132	68	68	NUM
njb-229	82	133	8	8	NUM
njb-229	82	134	piperacillin	piperacillin	PROPN
njb-229	82	135	-	-	PUNCT
njb-229	82	136	tazobactam	tazobactam	NOUN
njb-229	82	137	9	9	NUM
njb-229	82	138	(	(	PUNCT
njb-229	82	139	14.06	14.06	NUM
njb-229	82	140	)	)	PUNCT
njb-229	82	141	12	12	NUM
njb-229	82	142	(	(	PUNCT
njb-229	82	143	18.75	18.75	NUM
njb-229	82	144	)	)	PUNCT
njb-229	82	145	43	43	NUM
njb-229	82	146	(	(	PUNCT
njb-229	82	147	67.19	67.19	NUM
njb-229	82	148	)	)	PUNCT
njb-229	82	149	64	64	NUM
njb-229	82	150	9	9	NUM
njb-229	82	151	chloramphenicol	chloramphenicol	NOUN
njb-229	82	152	38	38	NUM
njb-229	82	153	(	(	PUNCT
njb-229	82	154	61.30	61.30	NUM
njb-229	82	155	)	)	PUNCT
njb-229	82	156	11(17.74	11(17.74	NUM
njb-229	82	157	)	)	PUNCT
njb-229	82	158	13	13	NUM
njb-229	82	159	(	(	PUNCT
njb-229	82	160	20.96	20.96	NUM
njb-229	82	161	)	)	PUNCT
njb-229	82	162	62	62	NUM
njb-229	82	163	10	10	NUM
njb-229	82	164	cotrimoxazole	cotrimoxazole	PROPN
njb-229	82	165	28	28	NUM
njb-229	82	166	(	(	PUNCT
njb-229	82	167	50	50	NUM
njb-229	82	168	)	)	PUNCT
njb-229	82	169	1	1	NUM
njb-229	82	170	(	(	PUNCT
njb-229	82	171	1.78	1.78	NUM
njb-229	82	172	)	)	PUNCT
njb-229	82	173	27	27	NUM
njb-229	82	174	(	(	PUNCT
njb-229	82	175	48.22	48.22	NUM
njb-229	82	176	)	)	PUNCT
njb-229	82	177	56	56	NUM
njb-229	82	178	11	11	NUM
njb-229	82	179	nitrofurantoin	nitrofurantoin	NOUN
njb-229	82	180	6	6	NUM
njb-229	82	181	(	(	PUNCT
njb-229	82	182	13	13	NUM
njb-229	82	183	)	)	PUNCT
njb-229	82	184	6	6	NUM
njb-229	82	185	(	(	PUNCT
njb-229	82	186	13	13	NUM
njb-229	82	187	)	)	PUNCT
njb-229	82	188	34	34	NUM
njb-229	82	189	(	(	PUNCT
njb-229	82	190	74	74	NUM
njb-229	82	191	)	)	PUNCT
njb-229	82	192	46	46	NUM
njb-229	82	193	nepal	nepal	PROPN
njb-229	82	194	j	j	PROPN
njb-229	82	195	biotechnol	biotechnol	PROPN
njb-229	82	196	.	.	PUNCT
njb-229	83	1	2	2	NUM
njb-229	83	2	0	0	NUM
njb-229	83	3	2	2	NUM
njb-229	83	4	2	2	NUM
njb-229	83	5	j	j	NOUN
njb-229	83	6	u	u	NOUN
njb-229	83	7	l	l	NOUN
njb-229	83	8	;	;	PUNCT
njb-229	83	9	1	1	NUM
njb-229	83	10	0	0	NUM
njb-229	83	11	(	(	PUNCT
njb-229	83	12	1):4	1):4	NUM
njb-229	83	13	0	0	NUM
njb-229	83	14	4	4	NUM
njb-229	83	15	4	4	NUM
njb-229	83	16	saud	saud	PROPN
njb-229	83	17	et	et	PROPN
njb-229	83	18	al	al	PROPN
njb-229	83	19	.	.	PUNCT
njb-229	84	1	©	©	PROPN
njb-229	84	2	njb	njb	PROPN
njb-229	84	3	,	,	PUNCT
njb-229	84	4	bsn	bsn	PROPN
njb-229	84	5	43	43	NUM
njb-229	84	6	ofloxacin	ofloxacin	PROPN
njb-229	84	7	are	be	AUX
njb-229	84	8	alternative	alternative	ADJ
njb-229	84	9	antibiotics	antibiotic	NOUN
njb-229	84	10	of	of	ADP
njb-229	84	11	choice	choice	NOUN
njb-229	84	12	if	if	SCONJ
njb-229	84	13	the	the	DET
njb-229	84	14	isolates	isolate	NOUN
njb-229	84	15	are	be	AUX
njb-229	84	16	esbl	esbl	PROPN
njb-229	84	17	producers	producer	NOUN
njb-229	84	18	.	.	PUNCT
njb-229	85	1	the	the	DET
njb-229	85	2	non	non	ADJ
njb-229	85	3	-	-	ADJ
njb-229	85	4	susceptibility	susceptibility	ADJ
njb-229	85	5	rates	rate	NOUN
njb-229	85	6	for	for	ADP
njb-229	85	7	ciprofloxacin	ciprofloxacin	NOUN
njb-229	85	8	and	and	CCONJ
njb-229	85	9	ofloxacin	ofloxacin	NOUN
njb-229	85	10	were	be	AUX
njb-229	85	11	57.65	57.65	NUM
njb-229	85	12	%	%	NOUN
njb-229	85	13	and	and	CCONJ
njb-229	85	14	55.3	55.3	NUM
njb-229	85	15	%	%	NOUN
njb-229	85	16	in	in	ADP
njb-229	85	17	our	our	PRON
njb-229	85	18	study	study	NOUN
njb-229	85	19	.	.	PUNCT
njb-229	86	1	similar	similar	ADJ
njb-229	86	2	to	to	ADP
njb-229	86	3	aminoglycosides	aminoglycoside	NOUN
njb-229	86	4	,	,	PUNCT
njb-229	86	5	a	a	DET
njb-229	86	6	wider	wide	ADJ
njb-229	86	7	range	range	NOUN
njb-229	86	8	of	of	ADP
njb-229	86	9	variations	variation	NOUN
njb-229	86	10	in	in	ADP
njb-229	86	11	the	the	DET
njb-229	86	12	non	non	NOUN
njb-229	86	13	-	-	NOUN
njb-229	86	14	susceptibility	susceptibility	NOUN
njb-229	86	15	of	of	ADP
njb-229	86	16	quinolones	quinolone	NOUN
njb-229	86	17	was	be	AUX
njb-229	86	18	observed	observe	VERB
njb-229	86	19	,	,	PUNCT
njb-229	86	20	ranging	range	VERB
njb-229	86	21	from	from	ADP
njb-229	86	22	less	less	ADJ
njb-229	86	23	than	than	ADP
njb-229	86	24	1	1	NUM
njb-229	86	25	%	%	NOUN
njb-229	86	26	to	to	ADP
njb-229	86	27	more	more	ADJ
njb-229	86	28	than	than	ADP
njb-229	86	29	90	90	NUM
njb-229	86	30	%	%	NOUN
njb-229	86	31	.	.	PUNCT
njb-229	87	1	the	the	DET
njb-229	87	2	study	study	NOUN
njb-229	87	3	of	of	ADP
njb-229	87	4	bulgaria	bulgaria	PROPN
njb-229	87	5	,	,	PUNCT
njb-229	87	6	italy	italy	PROPN
njb-229	87	7	,	,	PUNCT
njb-229	87	8	and	and	CCONJ
njb-229	87	9	romania	romania	PROPN
njb-229	87	10	was	be	AUX
njb-229	87	11	in	in	ADP
njb-229	87	12	line	line	NOUN
njb-229	87	13	with	with	ADP
njb-229	87	14	our	our	PRON
njb-229	87	15	study	study	NOUN
njb-229	87	16	,	,	PUNCT
njb-229	87	17	while	while	SCONJ
njb-229	87	18	from	from	ADP
njb-229	87	19	germany	germany	PROPN
njb-229	87	20	,	,	PUNCT
njb-229	87	21	denmark	denmark	PROPN
njb-229	87	22	,	,	PUNCT
njb-229	87	23	iran	iran	PROPN
njb-229	87	24	,	,	PUNCT
njb-229	87	25	and	and	CCONJ
njb-229	87	26	india	india	PROPN
njb-229	87	27	,	,	PUNCT
njb-229	87	28	the	the	DET
njb-229	87	29	non	non	ADJ
njb-229	87	30	-	-	ADJ
njb-229	87	31	susceptibility	susceptibility	ADJ
njb-229	87	32	rate	rate	NOUN
njb-229	87	33	was	be	AUX
njb-229	87	34	lower	low	ADJ
njb-229	87	35	than	than	ADP
njb-229	87	36	in	in	ADP
njb-229	87	37	our	our	PRON
njb-229	87	38	study	study	NOUN
njb-229	88	1	[	[	PUNCT
njb-229	88	2	19	19	NUM
njb-229	88	3	,	,	PUNCT
njb-229	88	4	21	21	NUM
njb-229	88	5	,	,	PUNCT
njb-229	88	6	22	22	NUM
njb-229	88	7	]	]	PUNCT
njb-229	88	8	.	.	PUNCT
njb-229	89	1	a	a	DET
njb-229	89	2	few	few	ADJ
njb-229	89	3	studies	study	NOUN
njb-229	89	4	from	from	ADP
njb-229	89	5	nepal	nepal	PROPN
njb-229	89	6	showed	show	VERB
njb-229	89	7	that	that	SCONJ
njb-229	89	8	the	the	DET
njb-229	89	9	resistance	resistance	NOUN
njb-229	89	10	rate	rate	NOUN
njb-229	89	11	is	be	AUX
njb-229	89	12	more	more	ADJ
njb-229	89	13	than	than	ADP
njb-229	89	14	85	85	NUM
njb-229	89	15	%	%	NOUN
njb-229	89	16	,	,	PUNCT
njb-229	89	17	which	which	PRON
njb-229	89	18	is	be	AUX
njb-229	89	19	quite	quite	ADV
njb-229	89	20	much	much	ADV
njb-229	89	21	higher	high	ADJ
njb-229	89	22	than	than	ADP
njb-229	89	23	ours	our	NOUN
njb-229	89	24	[	[	PUNCT
njb-229	89	25	23	23	NUM
njb-229	89	26	,	,	PUNCT
njb-229	89	27	25	25	NUM
njb-229	89	28	]	]	PUNCT
njb-229	89	29	.	.	PUNCT
njb-229	90	1	in	in	ADP
njb-229	90	2	general	general	ADJ
njb-229	90	3	,	,	PUNCT
njb-229	90	4	different	different	ADJ
njb-229	90	5	studies	study	NOUN
njb-229	90	6	conducted	conduct	VERB
njb-229	90	7	at	at	ADP
njb-229	90	8	different	different	ADJ
njb-229	90	9	times	time	NOUN
njb-229	90	10	revealed	reveal	VERB
njb-229	90	11	significant	significant	ADJ
njb-229	90	12	variability	variability	NOUN
njb-229	90	13	in	in	ADP
njb-229	90	14	antibiotic	antibiotic	ADJ
njb-229	90	15	resistance	resistance	NOUN
njb-229	90	16	patterns	pattern	NOUN
njb-229	90	17	.	.	PUNCT
njb-229	91	1	such	such	DET
njb-229	91	2	a	a	DET
njb-229	91	3	type	type	NOUN
njb-229	91	4	of	of	ADP
njb-229	91	5	variation	variation	NOUN
njb-229	91	6	was	be	AUX
njb-229	91	7	also	also	ADV
njb-229	91	8	observed	observe	VERB
njb-229	91	9	in	in	ADP
njb-229	91	10	other	other	ADJ
njb-229	91	11	antibiotics	antibiotic	NOUN
njb-229	91	12	mentioned	mention	VERB
njb-229	91	13	in	in	ADP
njb-229	91	14	table	table	NOUN
njb-229	91	15	2	2	NUM
njb-229	91	16	,	,	PUNCT
njb-229	91	17	which	which	PRON
njb-229	91	18	might	might	AUX
njb-229	91	19	be	be	AUX
njb-229	91	20	due	due	ADJ
njb-229	91	21	to	to	ADP
njb-229	91	22	the	the	DET
njb-229	91	23	low	low	ADJ
njb-229	91	24	number	number	NOUN
njb-229	91	25	of	of	ADP
njb-229	91	26	sample	sample	NOUN
njb-229	91	27	studies	study	NOUN
njb-229	91	28	or	or	CCONJ
njb-229	91	29	how	how	SCONJ
njb-229	91	30	meticulously	meticulously	ADV
njb-229	91	31	antibiotics	antibiotic	NOUN
njb-229	91	32	were	be	AUX
njb-229	91	33	used	use	VERB
njb-229	91	34	in	in	ADP
njb-229	91	35	that	that	DET
njb-229	91	36	country	country	NOUN
njb-229	91	37	to	to	PART
njb-229	91	38	mitigate	mitigate	VERB
njb-229	91	39	antibiotic	antibiotic	ADJ
njb-229	91	40	resistance	resistance	NOUN
njb-229	91	41	problems	problem	NOUN
njb-229	91	42	.	.	PUNCT
njb-229	92	1	hence	hence	ADV
njb-229	92	2	,	,	PUNCT
njb-229	92	3	resistance	resistance	NOUN
njb-229	92	4	to	to	ADP
njb-229	92	5	these	these	DET
njb-229	92	6	first	first	ADJ
njb-229	92	7	-	-	PUNCT
njb-229	92	8	line	line	NOUN
njb-229	92	9	agents	agent	NOUN
njb-229	92	10	represents	represent	VERB
njb-229	92	11	an	an	DET
njb-229	92	12	unprecedented	unprecedented	ADJ
njb-229	92	13	challenge	challenge	NOUN
njb-229	92	14	to	to	ADP
njb-229	92	15	clinicians	clinician	NOUN
njb-229	92	16	,	,	PUNCT
njb-229	92	17	scientists	scientist	NOUN
njb-229	92	18	,	,	PUNCT
njb-229	92	19	and	and	CCONJ
njb-229	92	20	healthcare	healthcare	NOUN
njb-229	92	21	systems	system	NOUN
njb-229	92	22	.	.	PUNCT
njb-229	93	1	carbapenems	carbapenems	PROPN
njb-229	93	2	(	(	PUNCT
njb-229	93	3	imipenem	imipenem	PROPN
njb-229	93	4	,	,	PUNCT
njb-229	93	5	meropenem	meropenem	PROPN
njb-229	93	6	,	,	PUNCT
njb-229	93	7	and	and	CCONJ
njb-229	93	8	ertapenem	ertapenem	PROPN
njb-229	93	9	)	)	PUNCT
njb-229	93	10	are	be	AUX
njb-229	93	11	the	the	DET
njb-229	93	12	antibiotics	antibiotic	NOUN
njb-229	93	13	of	of	ADP
njb-229	93	14	choice	choice	NOUN
njb-229	93	15	for	for	ADP
njb-229	93	16	those	those	DET
njb-229	93	17	k.	k.	NOUN
njb-229	93	18	pneumoniae	pneumoniae	NOUN
njb-229	93	19	that	that	PRON
njb-229	93	20	are	be	AUX
njb-229	93	21	mdr	mdr	NOUN
njb-229	93	22	and	and	CCONJ
njb-229	93	23	esbl	esbl	PROPN
njb-229	93	24	producers	producer	NOUN
njb-229	94	1	[	[	PUNCT
njb-229	94	2	26	26	NUM
njb-229	94	3	]	]	PUNCT
njb-229	94	4	.	.	PUNCT
njb-229	95	1	the	the	DET
njb-229	95	2	phenotypic	phenotypic	ADJ
njb-229	95	3	lab	lab	NOUN
njb-229	95	4	detection	detection	NOUN
njb-229	95	5	of	of	ADP
njb-229	95	6	carbapenem	carbapenem	PROPN
njb-229	95	7	resistance	resistance	NOUN
njb-229	95	8	is	be	AUX
njb-229	95	9	quite	quite	ADV
njb-229	95	10	confusing	confusing	ADJ
njb-229	95	11	and	and	CCONJ
njb-229	95	12	for	for	ADP
njb-229	95	13	confirmation	confirmation	NOUN
njb-229	95	14	of	of	ADP
njb-229	95	15	carbapenemase	carbapenemase	NOUN
njb-229	95	16	producer	producer	NOUN
njb-229	95	17	,	,	PUNCT
njb-229	95	18	different	different	ADJ
njb-229	95	19	additional	additional	ADJ
njb-229	95	20	tests	test	NOUN
njb-229	95	21	should	should	AUX
njb-229	95	22	be	be	AUX
njb-229	95	23	performed	perform	VERB
njb-229	95	24	[	[	SYM
njb-229	95	25	27	27	NUM
njb-229	95	26	]	]	PUNCT
njb-229	95	27	.	.	PUNCT
njb-229	96	1	therefore	therefore	ADV
njb-229	96	2	,	,	PUNCT
njb-229	96	3	clsi	clsi	PROPN
njb-229	96	4	recommends	recommend	VERB
njb-229	96	5	that	that	SCONJ
njb-229	96	6	ertapenem	ertapenem	PROPN
njb-229	96	7	non	non	ADJ
njb-229	96	8	-	-	NOUN
njb-229	96	9	susceptibility	susceptibility	NOUN
njb-229	96	10	is	be	AUX
njb-229	96	11	the	the	DET
njb-229	96	12	most	most	ADV
njb-229	96	13	sensitive	sensitive	ADJ
njb-229	96	14	indicator	indicator	NOUN
njb-229	96	15	for	for	ADP
njb-229	96	16	carbapenemase	carbapenemase	NOUN
njb-229	96	17	producers	producer	NOUN
njb-229	96	18	,	,	PUNCT
njb-229	96	19	and	and	CCONJ
njb-229	96	20	additional	additional	ADJ
njb-229	96	21	tests	test	NOUN
njb-229	96	22	should	should	AUX
njb-229	96	23	not	not	PART
njb-229	96	24	be	be	AUX
njb-229	96	25	performed	perform	VERB
njb-229	96	26	for	for	ADP
njb-229	96	27	purposes	purpose	NOUN
njb-229	96	28	other	other	ADJ
njb-229	96	29	than	than	ADP
njb-229	96	30	epidemiological	epidemiological	ADJ
njb-229	96	31	or	or	CCONJ
njb-229	96	32	infection	infection	NOUN
njb-229	96	33	control	control	NOUN
njb-229	96	34	after	after	ADP
njb-229	96	35	breaking	break	VERB
njb-229	96	36	point	point	NOUN
njb-229	96	37	evaluation	evaluation	NOUN
njb-229	96	38	of	of	ADP
njb-229	96	39	ertapenem	ertapenem	PROPN
njb-229	96	40	,	,	PUNCT
njb-229	96	41	meropenem	meropenem	PROPN
njb-229	96	42	,	,	PUNCT
njb-229	96	43	and	and	CCONJ
njb-229	96	44	imipenem	imipenem	PROPN
njb-229	97	1	[	[	PUNCT
njb-229	97	2	15	15	NUM
njb-229	97	3	]	]	PUNCT
njb-229	97	4	.	.	PUNCT
njb-229	98	1	in	in	ADP
njb-229	98	2	our	our	PRON
njb-229	98	3	study	study	NOUN
njb-229	98	4	,	,	PUNCT
njb-229	98	5	49	49	NUM
njb-229	98	6	(	(	PUNCT
njb-229	98	7	both	both	CCONJ
njb-229	98	8	intermediate	intermediate	ADJ
njb-229	98	9	and	and	CCONJ
njb-229	98	10	resistant	resistant	ADJ
njb-229	98	11	)	)	PUNCT
njb-229	98	12	isolates	isolate	NOUN
njb-229	98	13	showed	show	VERB
njb-229	98	14	positive	positive	ADJ
njb-229	98	15	screening	screening	NOUN
njb-229	98	16	through	through	ADP
njb-229	98	17	non	non	NOUN
njb-229	98	18	-	-	NOUN
njb-229	98	19	susceptibility	susceptibility	NOUN
njb-229	98	20	to	to	ADP
njb-229	98	21	ertapenem	ertapenem	PROPN
njb-229	98	22	.	.	PUNCT
njb-229	99	1	this	this	PRON
njb-229	99	2	suggests	suggest	VERB
njb-229	99	3	that	that	SCONJ
njb-229	99	4	resistance	resistance	NOUN
njb-229	99	5	to	to	ADP
njb-229	99	6	carbapenem	carbapenem	PROPN
njb-229	99	7	arises	arise	VERB
njb-229	99	8	due	due	ADP
njb-229	99	9	to	to	ADP
njb-229	99	10	the	the	DET
njb-229	99	11	formation	formation	NOUN
njb-229	99	12	of	of	ADP
njb-229	99	13	carbapenemase	carbapenemase	NOUN
njb-229	99	14	enzymes	enzyme	NOUN
njb-229	99	15	of	of	ADP
njb-229	99	16	classes	class	NOUN
njb-229	99	17	a	a	PROPN
njb-229	99	18	,	,	PUNCT
njb-229	99	19	b	b	PROPN
njb-229	99	20	and	and	CCONJ
njb-229	99	21	d	d	NOUN
njb-229	99	22	of	of	ADP
njb-229	99	23	the	the	DET
njb-229	99	24	amber	amber	ADJ
njb-229	99	25	class	class	NOUN
njb-229	99	26	of	of	ADP
njb-229	99	27	β	β	NOUN
njb-229	99	28	-	-	PUNCT
njb-229	99	29	lactamase	lactamase	NOUN
njb-229	99	30	,	,	PUNCT
njb-229	99	31	restricting	restrict	VERB
njb-229	99	32	the	the	DET
njb-229	99	33	treatment	treatment	NOUN
njb-229	99	34	option	option	NOUN
njb-229	99	35	[	[	PUNCT
njb-229	99	36	27	27	NUM
njb-229	99	37	]	]	PUNCT
njb-229	99	38	.	.	PUNCT
njb-229	100	1	the	the	DET
njb-229	100	2	crkp	crkp	PROPN
njb-229	100	3	was	be	AUX
njb-229	100	4	subjected	subject	VERB
njb-229	100	5	to	to	ADP
njb-229	100	6	the	the	DET
njb-229	100	7	etest	et	ADJ
njb-229	100	8	to	to	PART
njb-229	100	9	determine	determine	VERB
njb-229	100	10	the	the	DET
njb-229	100	11	mic	mic	NOUN
njb-229	100	12	of	of	ADP
njb-229	100	13	the	the	DET
njb-229	100	14	imipenem	imipenem	PROPN
njb-229	100	15	.	.	PUNCT
njb-229	101	1	the	the	DET
njb-229	101	2	test	test	NOUN
njb-229	101	3	results	result	NOUN
njb-229	101	4	showed	show	VERB
njb-229	101	5	that	that	SCONJ
njb-229	101	6	susceptible	susceptible	ADJ
njb-229	101	7	,	,	PUNCT
njb-229	101	8	intermediate	intermediate	ADJ
njb-229	101	9	and	and	CCONJ
njb-229	101	10	resistant	resistant	ADJ
njb-229	101	11	were	be	AUX
njb-229	101	12	13	13	NUM
njb-229	101	13	[	[	X
njb-229	101	14	mic	mic	PROPN
njb-229	101	15	≤1µg	≤1µg	PROPN
njb-229	101	16	/	/	SYM
njb-229	101	17	ml	ml	PROPN
njb-229	101	18	)	)	PUNCT
njb-229	101	19	,	,	PUNCT
njb-229	101	20	5	5	NUM
njb-229	101	21	[	[	X
njb-229	101	22	4µg	4µg	X
njb-229	101	23	/	/	SYM
njb-229	101	24	ml	ml	PROPN
njb-229	101	25	≤mic≥1µg	≤mic≥1µg	NUM
njb-229	101	26	/	/	SYM
njb-229	101	27	ml	ml	PROPN
njb-229	101	28	)	)	PUNCT
njb-229	101	29	and	and	CCONJ
njb-229	101	30	31	31	NUM
njb-229	101	31	[	[	PUNCT
njb-229	101	32	mic	mic	NOUN
njb-229	101	33	≥4	≥4	X
njb-229	101	34	μg	μg	PROPN
njb-229	101	35	/	/	SYM
njb-229	101	36	ml	ml	PROPN
njb-229	101	37	)	)	PUNCT
njb-229	101	38	,	,	PUNCT
njb-229	101	39	respectively	respectively	ADV
njb-229	101	40	.	.	PUNCT
njb-229	102	1	this	this	PRON
njb-229	102	2	implies	imply	VERB
njb-229	102	3	that	that	SCONJ
njb-229	102	4	results	result	NOUN
njb-229	102	5	from	from	ADP
njb-229	102	6	phenotypic	phenotypic	ADJ
njb-229	102	7	methods	method	NOUN
njb-229	102	8	can	can	AUX
njb-229	102	9	vary	vary	VERB
njb-229	102	10	,	,	PUNCT
njb-229	102	11	as	as	SCONJ
njb-229	102	12	suggested	suggest	VERB
njb-229	102	13	by	by	ADP
njb-229	102	14	clsi	clsi	NOUN
njb-229	102	15	.	.	PUNCT
njb-229	103	1	conclusions	conclusion	VERB
njb-229	103	2	the	the	DET
njb-229	103	3	fast	fast	ADV
njb-229	103	4	-	-	PUNCT
njb-229	103	5	growing	grow	VERB
njb-229	103	6	antibiotic	antibiotic	ADJ
njb-229	103	7	-	-	PUNCT
njb-229	103	8	resistant	resistant	ADJ
njb-229	103	9	klebsiella	klebsiella	PROPN
njb-229	103	10	pneumoniae	pneumoniae	NOUN
njb-229	103	11	is	be	AUX
njb-229	103	12	a	a	DET
njb-229	103	13	global	global	ADJ
njb-229	103	14	problem	problem	NOUN
njb-229	103	15	,	,	PUNCT
njb-229	103	16	including	include	VERB
njb-229	103	17	in	in	ADP
njb-229	103	18	nepal	nepal	ADJ
njb-229	103	19	,	,	PUNCT
njb-229	103	20	such	such	ADJ
njb-229	103	21	that	that	SCONJ
njb-229	103	22	the	the	DET
njb-229	103	23	choice	choice	NOUN
njb-229	103	24	of	of	ADP
njb-229	103	25	an	an	DET
njb-229	103	26	effective	effective	ADJ
njb-229	103	27	antibiotic	antibiotic	NOUN
njb-229	103	28	is	be	AUX
njb-229	103	29	now	now	ADV
njb-229	103	30	chaotic	chaotic	ADJ
njb-229	103	31	.	.	PUNCT
njb-229	104	1	the	the	DET
njb-229	104	2	continued	continue	VERB
njb-229	104	3	emergence	emergence	NOUN
njb-229	104	4	of	of	ADP
njb-229	104	5	crkp	crkp	PROPN
njb-229	104	6	has	have	AUX
njb-229	104	7	wreaked	wreak	VERB
njb-229	104	8	havoc	havoc	NOUN
njb-229	104	9	on	on	ADP
njb-229	104	10	its	its	PRON
njb-229	104	11	routine	routine	ADJ
njb-229	104	12	diagnosis	diagnosis	NOUN
njb-229	104	13	,	,	PUNCT
njb-229	104	14	as	as	ADV
njb-229	104	15	well	well	ADV
njb-229	104	16	as	as	ADP
njb-229	104	17	on	on	ADP
njb-229	104	18	its	its	PRON
njb-229	104	19	therapeutic	therapeutic	ADJ
njb-229	104	20	treatment	treatment	NOUN
njb-229	104	21	options	option	NOUN
njb-229	104	22	.	.	PUNCT
njb-229	105	1	susceptibility	susceptibility	NOUN
njb-229	105	2	testing	test	VERB
njb-229	105	3	[	[	PUNCT
njb-229	105	4	disc	disc	NOUN
njb-229	105	5	diffusion	diffusion	NOUN
njb-229	105	6	and	and	CCONJ
njb-229	105	7	mic	mic	NOUN
njb-229	105	8	)	)	PUNCT
njb-229	105	9	provides	provide	VERB
njb-229	105	10	valuable	valuable	ADJ
njb-229	105	11	information	information	NOUN
njb-229	105	12	for	for	ADP
njb-229	105	13	therapeutic	therapeutic	ADJ
njb-229	105	14	inference	inference	NOUN
njb-229	105	15	but	but	CCONJ
njb-229	105	16	does	do	AUX
njb-229	105	17	not	not	PART
njb-229	105	18	adequately	adequately	ADV
njb-229	105	19	address	address	VERB
njb-229	105	20	carbapenem	carbapenem	PROPN
njb-229	105	21	resistance	resistance	NOUN
njb-229	105	22	,	,	PUNCT
njb-229	105	23	which	which	PRON
njb-229	105	24	is	be	AUX
njb-229	105	25	significant	significant	ADJ
njb-229	105	26	for	for	ADP
njb-229	105	27	infection	infection	NOUN
njb-229	105	28	control	control	NOUN
njb-229	105	29	and	and	CCONJ
njb-229	105	30	epidemiological	epidemiological	ADJ
njb-229	105	31	evidence	evidence	NOUN
njb-229	105	32	necessary	necessary	ADJ
njb-229	105	33	to	to	PART
njb-229	105	34	curb	curb	VERB
njb-229	105	35	the	the	DET
njb-229	105	36	spread	spread	NOUN
njb-229	105	37	of	of	ADP
njb-229	105	38	carbapenem	carbapenem	NOUN
njb-229	105	39	-	-	PUNCT
njb-229	105	40	resistant	resistant	ADJ
njb-229	105	41	enterobacteriaceae	enterobacteriaceae	PROPN
njb-229	105	42	.	.	PUNCT
njb-229	106	1	authors	author	NOUN
njb-229	106	2	'	'	PART
njb-229	106	3	contributions	contribution	NOUN
njb-229	106	4	the	the	DET
njb-229	106	5	laboratory	laboratory	NOUN
njb-229	106	6	works	work	NOUN
njb-229	106	7	were	be	AUX
njb-229	106	8	performed	perform	VERB
njb-229	106	9	by	by	ADP
njb-229	106	10	sarada	sarada	PROPN
njb-229	106	11	saud	saud	PROPN
njb-229	106	12	,	,	PUNCT
njb-229	106	13	ashwani	ashwani	PROPN
njb-229	106	14	agrawal	agrawal	PROPN
njb-229	106	15	,	,	PUNCT
njb-229	106	16	soniya	soniya	PROPN
njb-229	106	17	pokhrel	pokhrel	PROPN
njb-229	106	18	and	and	CCONJ
njb-229	106	19	sushma	sushma	PROPN
njb-229	106	20	subedi	subedi	PROPN
njb-229	106	21	.	.	PUNCT
njb-229	107	1	research	research	NOUN
njb-229	107	2	conceptualization	conceptualization	NOUN
njb-229	107	3	,	,	PUNCT
njb-229	107	4	protocol	protocol	NOUN
njb-229	107	5	selection	selection	NOUN
njb-229	107	6	and	and	CCONJ
njb-229	107	7	preliminary	preliminary	ADJ
njb-229	107	8	manuscript	manuscript	NOUN
njb-229	107	9	preparation	preparation	NOUN
njb-229	107	10	were	be	AUX
njb-229	107	11	done	do	VERB
njb-229	107	12	by	by	ADP
njb-229	107	13	sarada	sarada	PROPN
njb-229	107	14	saud	saud	PROPN
njb-229	107	15	,	,	PUNCT
njb-229	107	16	ashwani	ashwani	PROPN
njb-229	107	17	agrawal	agrawal	PROPN
njb-229	107	18	,	,	PUNCT
njb-229	107	19	soniya	soniya	PROPN
njb-229	107	20	pokhrel	pokhrel	PROPN
njb-229	107	21	,	,	PUNCT
njb-229	107	22	sushma	sushma	PROPN
njb-229	107	23	subedi	subedi	PROPN
njb-229	107	24	,	,	PUNCT
njb-229	107	25	sanjit	sanjit	PROPN
njb-229	107	26	shrestha	shrestha	PROPN
njb-229	107	27	and	and	CCONJ
njb-229	107	28	niroj	niroj	PROPN
njb-229	107	29	man	man	PROPN
njb-229	107	30	amatya	amatya	PROPN
njb-229	107	31	.	.	PROPN
njb-229	108	1	final	final	ADJ
njb-229	108	2	manuscript	manuscript	PROPN
njb-229	108	3	preparation	preparation	NOUN
njb-229	108	4	was	be	AUX
njb-229	108	5	done	do	VERB
njb-229	108	6	by	by	ADP
njb-229	108	7	niroj	niroj	PROPN
njb-229	108	8	man	man	PROPN
njb-229	108	9	amatya	amatya	PROPN
njb-229	108	10	.	.	PUNCT
njb-229	109	1	the	the	DET
njb-229	109	2	study	study	NOUN
njb-229	109	3	was	be	AUX
njb-229	109	4	supervised	supervise	VERB
njb-229	109	5	under	under	ADP
njb-229	109	6	the	the	DET
njb-229	109	7	guidance	guidance	NOUN
njb-229	109	8	of	of	ADP
njb-229	109	9	sanjit	sanjit	PROPN
njb-229	109	10	shrestha	shrestha	PROPN
njb-229	109	11	and	and	CCONJ
njb-229	109	12	niroj	niroj	PROPN
njb-229	109	13	man	man	PROPN
njb-229	109	14	amatya	amatya	PROPN
njb-229	109	15	.	.	PUNCT
njb-229	110	1	all	all	DET
njb-229	110	2	authors	author	NOUN
njb-229	110	3	read	read	VERB
njb-229	110	4	and	and	CCONJ
njb-229	110	5	approved	approve	VERB
njb-229	110	6	the	the	DET
njb-229	110	7	final	final	ADJ
njb-229	110	8	manuscript	manuscript	NOUN
njb-229	110	9	.	.	PUNCT
njb-229	111	1	competing	compete	VERB
njb-229	111	2	interests	interest	NOUN
njb-229	111	3	on	on	ADP
njb-229	111	4	behalf	behalf	NOUN
njb-229	111	5	of	of	ADP
njb-229	111	6	all	all	DET
njb-229	111	7	authors	author	NOUN
njb-229	111	8	,	,	PUNCT
njb-229	111	9	the	the	DET
njb-229	111	10	corresponding	correspond	VERB
njb-229	111	11	author	author	NOUN
njb-229	111	12	states	state	VERB
njb-229	111	13	that	that	SCONJ
njb-229	111	14	there	there	PRON
njb-229	111	15	is	be	VERB
njb-229	111	16	no	no	DET
njb-229	111	17	competing	compete	VERB
njb-229	111	18	interest	interest	NOUN
njb-229	111	19	.	.	PUNCT
njb-229	112	1	financial	financial	ADJ
njb-229	112	2	disclosure	disclosure	NOUN
njb-229	112	3	it	it	PRON
njb-229	112	4	is	be	AUX
njb-229	112	5	a	a	DET
njb-229	112	6	self	self	NOUN
njb-229	112	7	-	-	PUNCT
njb-229	112	8	funded	fund	VERB
njb-229	112	9	pilot	pilot	NOUN
njb-229	112	10	study	study	NOUN
njb-229	112	11	and	and	CCONJ
njb-229	112	12	no	no	DET
njb-229	112	13	funding	funding	NOUN
njb-229	112	14	is	be	AUX
njb-229	112	15	granted	grant	VERB
njb-229	112	16	.	.	PUNCT
njb-229	113	1	acknowledgements	acknowledgement	VERB
njb-229	113	2	we	we	PRON
njb-229	113	3	would	would	AUX
njb-229	113	4	like	like	VERB
njb-229	113	5	to	to	PART
njb-229	113	6	thank	thank	VERB
njb-229	113	7	all	all	DET
njb-229	113	8	the	the	DET
njb-229	113	9	participants	participant	NOUN
njb-229	113	10	attained	attain	VERB
njb-229	113	11	in	in	ADP
njb-229	113	12	this	this	DET
njb-229	113	13	study	study	NOUN
njb-229	113	14	and	and	CCONJ
njb-229	113	15	the	the	DET
njb-229	113	16	pathology	pathology	PROPN
njb-229	113	17	department	department	PROPN
njb-229	113	18	of	of	ADP
njb-229	113	19	the	the	DET
njb-229	113	20	b	b	PROPN
njb-229	113	21	and	and	CCONJ
njb-229	113	22	b	b	PROPN
njb-229	113	23	hospital	hospital	NOUN
njb-229	113	24	,	,	PUNCT
njb-229	113	25	nepal	nepal	ADJ
njb-229	113	26	.	.	PUNCT
njb-229	114	1	ethics	ethic	NOUN
njb-229	114	2	approval	approval	VERB
njb-229	114	3	the	the	DET
njb-229	114	4	ethical	ethical	ADJ
njb-229	114	5	consent	consent	NOUN
njb-229	114	6	was	be	AUX
njb-229	114	7	procured	procure	VERB
njb-229	114	8	from	from	ADP
njb-229	114	9	nobel	nobel	PROPN
njb-229	114	10	institutional	institutional	PROPN
njb-229	114	11	review	review	PROPN
njb-229	114	12	committee	committee	NOUN
njb-229	114	13	[	[	X
njb-229	114	14	irc	irc	NOUN
njb-229	114	15	)	)	PUNCT
njb-229	114	16	with	with	ADP
njb-229	114	17	reference	reference	NOUN
njb-229	114	18	number	number	NOUN
njb-229	114	19	bch	bch	PROPN
njb-229	114	20	irc	irc	PROPN
njb-229	114	21	161/2018	161/2018	NUM
njb-229	114	22	.	.	PUNCT
njb-229	115	1	additional	additional	ADJ
njb-229	115	2	disclosure	disclosure	NOUN
njb-229	115	3	this	this	DET
njb-229	115	4	manuscript	manuscript	NOUN
njb-229	115	5	has	have	AUX
njb-229	115	6	been	be	AUX
njb-229	115	7	already	already	ADV
njb-229	115	8	published	publish	VERB
njb-229	115	9	in	in	ADP
njb-229	115	10	preprint	preprint	NOUN
njb-229	115	11	form	form	NOUN
njb-229	115	12	with	with	ADP
njb-229	115	13	title	title	NOUN
njb-229	115	14	“	"	PUNCT
njb-229	115	15	screening	screen	VERB
njb-229	115	16	ofklebsiella	ofklebsiella	PROPN
njb-229	115	17	pneumoniaefor	pneumoniaefor	PROPN
njb-229	115	18	carbapenem	carbapenem	PROPN
njb-229	115	19	resistance	resistance	NOUN
njb-229	115	20	and	and	CCONJ
njb-229	115	21	mic	mic	NOUN
njb-229	115	22	of	of	ADP
njb-229	115	23	imipenem	imipenem	PROPN
njb-229	115	24	”	"	PUNCT
njb-229	115	25	with	with	ADP
njb-229	115	26	weblink	weblink	NOUN
njb-229	115	27	:	:	PUNCT
njb-229	115	28	https://www.researchsquare.com/article/rs36584/v1	https://www.researchsquare.com/article/rs36584/v1	PROPN
njb-229	115	29	reference	reference	NOUN
njb-229	115	30	1	1	NUM
njb-229	115	31	.	.	PUNCT
njb-229	116	1	broberg	broberg	PROPN
njb-229	116	2	ca	can	AUX
njb-229	116	3	,	,	PUNCT
njb-229	116	4	palacios	palacio	NOUN
njb-229	116	5	m	m	PROPN
njb-229	116	6	,	,	PUNCT
njb-229	117	1	miller	miller	PROPN
njb-229	117	2	vl	vl	PROPN
njb-229	117	3	.	.	PROPN
njb-229	117	4	klebsiella	klebsiella	PROPN
njb-229	117	5	:	:	PUNCT
njb-229	117	6	a	a	DET
njb-229	117	7	long	long	ADJ
njb-229	117	8	way	way	NOUN
njb-229	117	9	to	to	PART
njb-229	117	10	go	go	VERB
njb-229	117	11	towards	towards	ADP
njb-229	117	12	understanding	understand	VERB
njb-229	117	13	this	this	DET
njb-229	117	14	enigmatic	enigmatic	ADJ
njb-229	117	15	jet	jet	NOUN
njb-229	117	16	-	-	PUNCT
njb-229	117	17	setter	setter	NOUN
njb-229	117	18	.	.	PUNCT
njb-229	118	1	f1000prime	f1000prime	PROPN
njb-229	118	2	rep	rep	PROPN
njb-229	118	3	.	.	PROPN
njb-229	118	4	2014;6:64	2014;6:64	NUM
njb-229	118	5	.	.	PUNCT
njb-229	118	6	2	2	NUM
njb-229	118	7	.	.	PROPN
njb-229	118	8	paczosa	paczosa	PROPN
njb-229	118	9	mk	mk	PROPN
njb-229	118	10	,	,	PUNCT
njb-229	118	11	mecsas	mecsas	PROPN
njb-229	118	12	j.	j.	PROPN
njb-229	118	13	klebsiella	klebsiella	PROPN
njb-229	118	14	pneumoniae	pneumoniae	PROPN
njb-229	118	15	:	:	PUNCT
njb-229	118	16	going	go	VERB
njb-229	118	17	on	on	ADP
njb-229	118	18	the	the	DET
njb-229	118	19	offense	offense	NOUN
njb-229	118	20	with	with	ADP
njb-229	118	21	a	a	DET
njb-229	118	22	strong	strong	ADJ
njb-229	118	23	defense	defense	NOUN
njb-229	118	24	.	.	PUNCT
njb-229	119	1	microbiol	microbiol	PROPN
njb-229	119	2	mol	mol	PROPN
njb-229	119	3	biol	biol	PROPN
njb-229	119	4	rev	rev	PROPN
njb-229	119	5	.	.	PUNCT
njb-229	120	1	2016;80[3):629	2016;80[3):629	NUM
njb-229	120	2	-	-	SYM
njb-229	120	3	61	61	NUM
njb-229	120	4	3	3	NUM
njb-229	120	5	.	.	X
njb-229	121	1	who	who	PRON
njb-229	121	2	.	.	PUNCT
njb-229	122	1	antimicrobial	antimicrobial	ADJ
njb-229	122	2	resistance	resistance	NOUN
njb-229	122	3	:	:	PUNCT
njb-229	122	4	global	global	ADJ
njb-229	122	5	report	report	NOUN
njb-229	122	6	on	on	ADP
njb-229	122	7	surveillance	surveillance	NOUN
njb-229	122	8	.	.	PUNCT
njb-229	123	1	geneva	geneva	PROPN
njb-229	123	2	,	,	PUNCT
njb-229	123	3	switzerland	switzerland	PROPN
njb-229	123	4	:	:	PUNCT
njb-229	123	5	world	world	PROPN
njb-229	123	6	health	health	NOUN
njb-229	123	7	organization	organization	NOUN
njb-229	123	8	;	;	PUNCT
njb-229	123	9	2014	2014	NUM
njb-229	123	10	.	.	PUNCT
njb-229	124	1	4	4	X
njb-229	124	2	.	.	X
njb-229	124	3	queenan	queenan	PROPN
njb-229	124	4	am	be	AUX
njb-229	124	5	,	,	PUNCT
njb-229	124	6	bush	bush	PROPN
njb-229	124	7	k.	k.	NOUN
njb-229	124	8	carbapenemases	carbapenemase	NOUN
njb-229	124	9	:	:	PUNCT
njb-229	124	10	the	the	DET
njb-229	124	11	versatile	versatile	ADJ
njb-229	124	12	β	β	NOUN
njb-229	124	13	-	-	PUNCT
njb-229	124	14	lactamases	lactamase	NOUN
njb-229	124	15	.	.	PUNCT
njb-229	125	1	clinical	clinical	ADJ
njb-229	125	2	microbiology	microbiology	NOUN
njb-229	125	3	reviews	review	NOUN
njb-229	125	4	.	.	PUNCT
njb-229	126	1	2007;20(3):440	2007;20(3):440	NUM
njb-229	126	2	-	-	PUNCT
njb-229	126	3	58	58	NUM
njb-229	126	4	5	5	NUM
njb-229	126	5	.	.	PUNCT
njb-229	127	1	martínez	martínez	PROPN
njb-229	127	2	-	-	PUNCT
njb-229	127	3	martínez	martínez	PROPN
njb-229	127	4	l	l	NOUN
njb-229	127	5	,	,	PUNCT
njb-229	127	6	pascual	pascual	ADJ
njb-229	127	7	a	a	PRON
njb-229	127	8	,	,	PUNCT
njb-229	127	9	hernández	hernández	PROPN
njb-229	127	10	-	-	PUNCT
njb-229	127	11	allés	allés	PROPN
njb-229	127	12	s	s	PROPN
njb-229	127	13	,	,	PUNCT
njb-229	127	14	alvarez	alvarez	PROPN
njb-229	127	15	-	-	PUNCT
njb-229	127	16	díaz	díaz	PROPN
njb-229	127	17	d	d	PROPN
njb-229	127	18	,	,	PUNCT
njb-229	127	19	suárez	suárez	PROPN
njb-229	127	20	ai	ai	VERB
njb-229	127	21	,	,	PUNCT
njb-229	127	22	tran	tran	PROPN
njb-229	127	23	j	j	NOUN
njb-229	127	24	,	,	PUNCT
njb-229	127	25	et	et	PROPN
njb-229	127	26	al	al	PROPN
njb-229	127	27	.	.	PUNCT
njb-229	128	1	roles	role	NOUN
njb-229	128	2	of	of	ADP
njb-229	128	3	β	β	NOUN
njb-229	128	4	-	-	PUNCT
njb-229	128	5	lactamases	lactamase	NOUN
njb-229	128	6	and	and	CCONJ
njb-229	128	7	porins	porin	NOUN
njb-229	128	8	in	in	ADP
njb-229	128	9	activities	activity	NOUN
njb-229	128	10	of	of	ADP
njb-229	128	11	carbapenems	carbapenem	NOUN
njb-229	128	12	and	and	CCONJ
njb-229	128	13	cephalosporins	cephalosporin	NOUN
njb-229	128	14	against	against	ADP
njb-229	128	15	klebsiella	klebsiella	PROPN
njb-229	128	16	nepal	nepal	PROPN
njb-229	128	17	j	j	PROPN
njb-229	128	18	biotechnol	biotechnol	PROPN
njb-229	128	19	.	.	PUNCT
njb-229	129	1	2	2	NUM
njb-229	129	2	0	0	NUM
njb-229	129	3	2	2	NUM
njb-229	129	4	2	2	NUM
njb-229	129	5	j	j	NOUN
njb-229	129	6	u	u	NOUN
njb-229	129	7	l	l	NOUN
njb-229	129	8	;	;	PUNCT
njb-229	129	9	1	1	NUM
njb-229	129	10	0	0	NUM
njb-229	129	11	(	(	PUNCT
njb-229	129	12	1):4	1):4	NUM
njb-229	129	13	0	0	NUM
njb-229	129	14	4	4	NUM
njb-229	129	15	4	4	NUM
njb-229	129	16	saud	saud	PROPN
njb-229	129	17	et	et	PROPN
njb-229	129	18	al	al	PROPN
njb-229	129	19	.	.	PUNCT
njb-229	130	1	©	©	PROPN
njb-229	130	2	njb	njb	PROPN
njb-229	130	3	,	,	PUNCT
njb-229	130	4	bsn	bsn	PROPN
njb-229	130	5	44	44	NUM
njb-229	130	6	pneumoniae	pneumoniae	NOUN
njb-229	130	7	.	.	PUNCT
njb-229	131	1	antimicrobial	antimicrobial	ADJ
njb-229	131	2	agents	agent	NOUN
njb-229	131	3	and	and	CCONJ
njb-229	131	4	chemotherapy	chemotherapy	NOUN
njb-229	131	5	.	.	PUNCT
njb-229	132	1	1999;43(7):1669	1999;43(7):1669	NUM
njb-229	132	2	-	-	SYM
njb-229	132	3	73	73	NUM
njb-229	132	4	6	6	NUM
njb-229	132	5	.	.	PUNCT
njb-229	132	6	padilla	padilla	PROPN
njb-229	132	7	e	e	PROPN
njb-229	132	8	,	,	PUNCT
njb-229	132	9	llobet	llobet	PROPN
njb-229	132	10	e	e	PROPN
njb-229	132	11	,	,	PUNCT
njb-229	132	12	doménech	doménech	PROPN
njb-229	132	13	-	-	PUNCT
njb-229	132	14	sánchez	sánchez	PROPN
njb-229	132	15	a	a	PRON
njb-229	132	16	,	,	PUNCT
njb-229	132	17	martínez	martínez	PROPN
njb-229	132	18	-	-	PUNCT
njb-229	132	19	martínez	martínez	PROPN
njb-229	132	20	l	l	PROPN
njb-229	132	21	,	,	PUNCT
njb-229	132	22	bengoechea	bengoechea	PROPN
njb-229	132	23	ja	ja	PROPN
njb-229	132	24	,	,	PUNCT
njb-229	132	25	albertí	albertí	PROPN
njb-229	132	26	s.	s.	PROPN
njb-229	132	27	klebsiella	klebsiella	PROPN
njb-229	132	28	pneumoniae	pneumoniae	PROPN
njb-229	132	29	acrab	acrab	ADJ
njb-229	132	30	efflux	efflux	NOUN
njb-229	132	31	pump	pump	NOUN
njb-229	132	32	contributes	contribute	VERB
njb-229	132	33	to	to	ADP
njb-229	132	34	antimicrobial	antimicrobial	ADJ
njb-229	132	35	resistance	resistance	NOUN
njb-229	132	36	and	and	CCONJ
njb-229	132	37	virulence	virulence	NOUN
njb-229	132	38	.	.	PUNCT
njb-229	133	1	antimicrobial	antimicrobial	ADJ
njb-229	133	2	agents	agent	NOUN
njb-229	133	3	and	and	CCONJ
njb-229	133	4	chemotherapy	chemotherapy	NOUN
njb-229	133	5	.	.	PUNCT
njb-229	134	1	2010;54(1):177	2010;54(1):177	NUM
njb-229	134	2	-	-	SYM
njb-229	134	3	83	83	NUM
njb-229	134	4	7	7	NUM
njb-229	134	5	.	.	PUNCT
njb-229	135	1	who	who	PRON
njb-229	135	2	.	.	PUNCT
njb-229	136	1	global	global	ADJ
njb-229	136	2	priority	priority	NOUN
njb-229	136	3	list	list	NOUN
njb-229	136	4	of	of	ADP
njb-229	136	5	antibiotic	antibiotic	ADJ
njb-229	136	6	-	-	PUNCT
njb-229	136	7	resistant	resistant	ADJ
njb-229	136	8	bacteria	bacteria	NOUN
njb-229	136	9	to	to	PART
njb-229	136	10	guide	guide	VERB
njb-229	136	11	research	research	NOUN
njb-229	136	12	,	,	PUNCT
njb-229	136	13	discovery	discovery	NOUN
njb-229	136	14	,	,	PUNCT
njb-229	136	15	and	and	CCONJ
njb-229	136	16	development	development	NOUN
njb-229	136	17	of	of	ADP
njb-229	136	18	new	new	ADJ
njb-229	136	19	antibiotics	antibiotic	NOUN
njb-229	136	20	.	.	PUNCT
njb-229	137	1	february	february	PROPN
njb-229	137	2	27	27	NUM
njb-229	137	3	,	,	PUNCT
njb-229	137	4	2017	2017	NUM
njb-229	137	5	.	.	PUNCT
njb-229	137	6	2018	2018	NUM
njb-229	137	7	.	.	PUNCT
njb-229	138	1	8	8	NUM
njb-229	138	2	.	.	X
njb-229	138	3	munoz	munoz	NOUN
njb-229	138	4	-	-	PUNCT
njb-229	138	5	price	price	NOUN
njb-229	138	6	ls	l	NOUN
njb-229	138	7	,	,	PUNCT
njb-229	138	8	poirel	poirel	PROPN
njb-229	138	9	l	l	PROPN
njb-229	138	10	,	,	PUNCT
njb-229	138	11	bonomo	bonomo	NOUN
njb-229	138	12	ra	ra	PROPN
njb-229	138	13	,	,	PUNCT
njb-229	138	14	schwaber	schwaber	PROPN
njb-229	138	15	mj	mj	PROPN
njb-229	138	16	,	,	PUNCT
njb-229	138	17	daikos	daikos	PROPN
njb-229	138	18	gl	gl	PROPN
njb-229	138	19	,	,	PUNCT
njb-229	138	20	cormican	cormican	PROPN
njb-229	138	21	m	m	PROPN
njb-229	138	22	,	,	PUNCT
njb-229	138	23	et	et	PROPN
njb-229	138	24	al	al	PROPN
njb-229	138	25	.	.	PUNCT
njb-229	139	1	clinical	clinical	ADJ
njb-229	139	2	epidemiology	epidemiology	NOUN
njb-229	139	3	of	of	ADP
njb-229	139	4	the	the	DET
njb-229	139	5	global	global	ADJ
njb-229	139	6	expansion	expansion	NOUN
njb-229	139	7	of	of	ADP
njb-229	139	8	klebsiella	klebsiella	PROPN
njb-229	139	9	pneumoniae	pneumoniae	NOUN
njb-229	139	10	carbapenemases	carbapenemase	NOUN
njb-229	139	11	.	.	PUNCT
njb-229	140	1	the	the	DET
njb-229	140	2	lancet	lancet	PROPN
njb-229	140	3	infectious	infectious	ADJ
njb-229	140	4	diseases	disease	NOUN
njb-229	140	5	.	.	PUNCT
njb-229	141	1	2013;13(9):785	2013;13(9):785	NUM
njb-229	141	2	-	-	SYM
njb-229	141	3	96	96	NUM
njb-229	141	4	9	9	NUM
njb-229	141	5	.	.	PUNCT
njb-229	142	1	xu	xu	PROPN
njb-229	142	2	l	l	PROPN
njb-229	142	3	,	,	PUNCT
njb-229	142	4	sun	sun	PROPN
njb-229	142	5	x	x	PROPN
njb-229	142	6	,	,	PUNCT
njb-229	142	7	ma	ma	PROPN
njb-229	142	8	x.	x.	PROPN
njb-229	142	9	systematic	systematic	PROPN
njb-229	142	10	review	review	PROPN
njb-229	142	11	and	and	CCONJ
njb-229	142	12	meta	meta	NOUN
njb-229	142	13	-	-	PUNCT
njb-229	142	14	analysis	analysis	NOUN
njb-229	142	15	of	of	ADP
njb-229	142	16	mortality	mortality	NOUN
njb-229	142	17	of	of	ADP
njb-229	142	18	patients	patient	NOUN
njb-229	142	19	infected	infect	VERB
njb-229	142	20	with	with	ADP
njb-229	142	21	carbapenem	carbapenem	PROPN
njb-229	142	22	-	-	PUNCT
njb-229	142	23	resistant	resistant	ADJ
njb-229	142	24	klebsiella	klebsiella	PROPN
njb-229	142	25	pneumoniae	pneumoniae	NOUN
njb-229	142	26	.	.	PUNCT
njb-229	143	1	annals	annal	NOUN
njb-229	143	2	of	of	ADP
njb-229	143	3	clinical	clinical	ADJ
njb-229	143	4	microbiology	microbiology	NOUN
njb-229	143	5	and	and	CCONJ
njb-229	143	6	antimicrobials	antimicrobial	NOUN
njb-229	143	7	.	.	PUNCT
njb-229	143	8	2017;16(1):18	2017;16(1):18	NUM
njb-229	143	9	.	.	PUNCT
njb-229	144	1	10	10	NUM
njb-229	144	2	.	.	PUNCT
njb-229	144	3	european	european	PROPN
njb-229	144	4	centre	centre	PROPN
njb-229	144	5	for	for	ADP
njb-229	144	6	disease	disease	NOUN
njb-229	144	7	prevention	prevention	NOUN
njb-229	144	8	and	and	CCONJ
njb-229	144	9	control	control	NOUN
njb-229	144	10	.	.	PUNCT
njb-229	145	1	surveillance	surveillance	NOUN
njb-229	145	2	atlas	atlas	NOUN
njb-229	145	3	of	of	ADP
njb-229	145	4	infectious	infectious	ADJ
njb-229	145	5	diseases	disease	NOUN
njb-229	145	6	:	:	PUNCT
njb-229	145	7	ecdc	ecdc	NOUN
njb-229	145	8	;	;	PUNCT
njb-229	146	1	[	[	X
njb-229	146	2	available	available	ADJ
njb-229	146	3	from	from	ADP
njb-229	146	4	:	:	PUNCT
njb-229	146	5	http://atlas.ecdc.europa.eu/public/index.aspx?instance	http://atlas.ecdc.europa.eu/public/index.aspx?instance	X
njb-229	146	6	.	.	PROPN
njb-229	146	7	11	11	NUM
njb-229	146	8	.	.	PUNCT
njb-229	147	1	nordmann	nordmann	PROPN
njb-229	147	2	p	p	PROPN
njb-229	147	3	,	,	PUNCT
njb-229	147	4	poirel	poirel	PROPN
njb-229	147	5	l.	l.	PROPN
njb-229	148	1	the	the	DET
njb-229	148	2	difficult	difficult	ADJ
njb-229	148	3	-	-	PUNCT
njb-229	148	4	to	to	ADP
njb-229	148	5	-	-	PUNCT
njb-229	148	6	control	control	NOUN
njb-229	148	7	spread	spread	NOUN
njb-229	148	8	of	of	ADP
njb-229	148	9	carbapenemase	carbapenemase	NOUN
njb-229	148	10	producers	producer	NOUN
njb-229	148	11	among	among	ADP
njb-229	148	12	enterobacteriaceae	enterobacteriaceae	PROPN
njb-229	148	13	worldwide	worldwide	ADV
njb-229	148	14	.	.	PUNCT
njb-229	149	1	clinical	clinical	ADJ
njb-229	149	2	microbiology	microbiology	NOUN
njb-229	149	3	and	and	CCONJ
njb-229	149	4	infection	infection	NOUN
njb-229	149	5	.	.	PUNCT
njb-229	150	1	2014;20(9):821	2014;20(9):821	NUM
njb-229	150	2	-	-	SYM
njb-229	150	3	30	30	NUM
njb-229	150	4	12	12	NUM
njb-229	150	5	.	.	PUNCT
njb-229	151	1	leber	leber	PROPN
njb-229	151	2	al	al	PROPN
njb-229	151	3	.	.	PROPN
njb-229	152	1	clinical	clinical	ADJ
njb-229	152	2	microbiology	microbiology	NOUN
njb-229	152	3	procedures	procedure	NOUN
njb-229	152	4	handbook	handbook	PROPN
njb-229	152	5	.	.	PUNCT
njb-229	153	1	washington	washington	PROPN
njb-229	153	2	,	,	PUNCT
njb-229	153	3	dc	dc	PROPN
njb-229	153	4	,	,	PUNCT
njb-229	153	5	usa	usa	PROPN
njb-229	153	6	:	:	PUNCT
njb-229	153	7	american	american	PROPN
njb-229	153	8	society	society	PROPN
njb-229	153	9	for	for	ADP
njb-229	153	10	microbiology	microbiology	NOUN
njb-229	153	11	;	;	PUNCT
njb-229	153	12	2016	2016	NUM
njb-229	153	13	.	.	PUNCT
njb-229	154	1	13	13	NUM
njb-229	154	2	.	.	PUNCT
njb-229	155	1	tille	tille	PROPN
njb-229	155	2	p.	p.	PROPN
njb-229	155	3	bailey	bailey	PROPN
njb-229	155	4	&	&	CCONJ
njb-229	155	5	scott	scott	PROPN
njb-229	155	6	's	's	PART
njb-229	155	7	diagnostic	diagnostic	ADJ
njb-229	155	8	microbiology	microbiology	NOUN
njb-229	155	9	:	:	PUNCT
njb-229	155	10	elsevier	elsevier	VERB
njb-229	155	11	health	health	NOUN
njb-229	155	12	sciences	science	NOUN
njb-229	155	13	;	;	PUNCT
njb-229	155	14	2015	2015	NUM
njb-229	155	15	.	.	PUNCT
njb-229	155	16	14	14	NUM
njb-229	155	17	.	.	PUNCT
njb-229	156	1	magiorakos	magiorakos	PROPN
njb-229	156	2	ap	ap	PROPN
njb-229	156	3	,	,	PUNCT
njb-229	156	4	srinivasan	srinivasan	VERB
njb-229	156	5	a	a	PRON
njb-229	156	6	,	,	PUNCT
njb-229	156	7	carey	carey	NOUN
njb-229	156	8	rb	rb	NOUN
njb-229	156	9	,	,	PUNCT
njb-229	156	10	carmeli	carmeli	PROPN
njb-229	156	11	y	y	PROPN
njb-229	156	12	,	,	PUNCT
njb-229	156	13	falagas	falagas	VERB
njb-229	156	14	me	i	PRON
njb-229	156	15	,	,	PUNCT
njb-229	156	16	giske	giske	PROPN
njb-229	156	17	cg	cg	PROPN
njb-229	156	18	,	,	PUNCT
njb-229	156	19	et	et	PROPN
njb-229	156	20	al	al	PROPN
njb-229	156	21	.	.	PUNCT
njb-229	157	1	multidrug‐resistant	multidrug‐resistant	PROPN
njb-229	157	2	,	,	PUNCT
njb-229	157	3	extensively	extensively	ADV
njb-229	157	4	drug‐resistant	drug‐resistant	NOUN
njb-229	157	5	and	and	CCONJ
njb-229	157	6	pandrug‐resistant	pandrug‐resistant	ADJ
njb-229	157	7	bacteria	bacteria	NOUN
njb-229	157	8	:	:	PUNCT
njb-229	157	9	an	an	DET
njb-229	157	10	international	international	ADJ
njb-229	157	11	expert	expert	NOUN
njb-229	157	12	proposal	proposal	NOUN
njb-229	157	13	for	for	ADP
njb-229	157	14	interim	interim	ADJ
njb-229	157	15	standard	standard	ADJ
njb-229	157	16	definitions	definition	NOUN
njb-229	157	17	for	for	ADP
njb-229	157	18	acquired	acquire	VERB
njb-229	157	19	resistance	resistance	NOUN
njb-229	157	20	.	.	PUNCT
njb-229	158	1	clinical	clinical	ADJ
njb-229	158	2	microbiology	microbiology	NOUN
njb-229	158	3	and	and	CCONJ
njb-229	158	4	infection	infection	NOUN
njb-229	158	5	.	.	PUNCT
njb-229	159	1	2012;18(3):268	2012;18(3):268	NUM
njb-229	159	2	-	-	SYM
njb-229	159	3	81	81	NUM
njb-229	159	4	15	15	NUM
njb-229	159	5	.	.	PUNCT
njb-229	160	1	clsi	clsi	PROPN
njb-229	160	2	.	.	PUNCT
njb-229	161	1	performance	performance	NOUN
njb-229	161	2	standards	standard	NOUN
njb-229	161	3	for	for	ADP
njb-229	161	4	antimicrobial	antimicrobial	ADJ
njb-229	161	5	susceptibility	susceptibility	NOUN
njb-229	161	6	testing	testing	NOUN
njb-229	161	7	.	.	PUNCT
njb-229	162	1	wayne	wayne	PROPN
njb-229	162	2	,	,	PUNCT
njb-229	162	3	pa	pa	PROPN
njb-229	162	4	:	:	PUNCT
njb-229	162	5	clinical	clinical	ADJ
njb-229	162	6	and	and	CCONJ
njb-229	162	7	laboratory	laboratory	PROPN
njb-229	162	8	standards	standards	PROPN
njb-229	162	9	institute	institute	PROPN
njb-229	162	10	;	;	PUNCT
njb-229	162	11	2018	2018	NUM
njb-229	162	12	.	.	PUNCT
njb-229	163	1	16	16	NUM
njb-229	163	2	.	.	PUNCT
njb-229	164	1	lin	lin	PROPN
njb-229	164	2	my	my	PRON
njb-229	164	3	,	,	PUNCT
njb-229	164	4	lyles	lyle	NOUN
njb-229	164	5	-	-	PUNCT
njb-229	164	6	banks	bank	NOUN
njb-229	164	7	rd	rd	PROPN
njb-229	164	8	,	,	PUNCT
njb-229	164	9	lolans	lolans	PROPN
njb-229	164	10	k	k	PROPN
njb-229	164	11	,	,	PUNCT
njb-229	164	12	hines	hines	PROPN
njb-229	164	13	dw	dw	PROPN
njb-229	164	14	,	,	PUNCT
njb-229	164	15	spear	spear	PROPN
njb-229	164	16	jb	jb	PROPN
njb-229	164	17	,	,	PUNCT
njb-229	164	18	petrak	petrak	PROPN
njb-229	164	19	r	r	PROPN
njb-229	164	20	,	,	PUNCT
njb-229	164	21	et	et	PROPN
njb-229	164	22	al	al	PROPN
njb-229	164	23	.	.	PUNCT
njb-229	165	1	the	the	DET
njb-229	165	2	importance	importance	NOUN
njb-229	165	3	of	of	ADP
njb-229	165	4	long	long	ADJ
njb-229	165	5	-	-	PUNCT
njb-229	165	6	term	term	NOUN
njb-229	165	7	acute	acute	ADJ
njb-229	165	8	care	care	NOUN
njb-229	165	9	hospitals	hospital	NOUN
njb-229	165	10	in	in	ADP
njb-229	165	11	the	the	DET
njb-229	165	12	regional	regional	ADJ
njb-229	165	13	epidemiology	epidemiology	NOUN
njb-229	165	14	of	of	ADP
njb-229	165	15	klebsiella	klebsiella	PROPN
njb-229	165	16	pneumoniae	pneumoniae	NOUN
njb-229	165	17	carbapenemase	carbapenemase	PROPN
njb-229	165	18	–	–	PUNCT
njb-229	165	19	producing	produce	VERB
njb-229	165	20	enterobacteriaceae	enterobacteriaceae	PROPN
njb-229	165	21	.	.	PUNCT
njb-229	166	1	clinical	clinical	ADJ
njb-229	166	2	infectious	infectious	ADJ
njb-229	166	3	diseases	disease	NOUN
njb-229	166	4	.	.	PUNCT
njb-229	167	1	2013;57(9):1246	2013;57(9):1246	PROPN
njb-229	167	2	-	-	PUNCT
njb-229	167	3	52	52	NUM
njb-229	167	4	17	17	NUM
njb-229	167	5	.	.	PUNCT
njb-229	168	1	mandell	mandell	PROPN
njb-229	168	2	g	g	PROPN
njb-229	168	3	,	,	PUNCT
njb-229	168	4	dolin	dolin	PROPN
njb-229	168	5	r	r	PROPN
njb-229	168	6	,	,	PUNCT
njb-229	168	7	bennett	bennett	PROPN
njb-229	168	8	j.	j.	PROPN
njb-229	168	9	mandell	mandell	PROPN
njb-229	168	10	,	,	PUNCT
njb-229	168	11	douglas	douglas	PROPN
njb-229	168	12	,	,	PUNCT
njb-229	168	13	and	and	CCONJ
njb-229	168	14	bennett	bennett	PROPN
njb-229	168	15	's	's	PART
njb-229	168	16	principles	principle	NOUN
njb-229	168	17	and	and	CCONJ
njb-229	168	18	practice	practice	NOUN
njb-229	168	19	of	of	ADP
njb-229	168	20	infectious	infectious	ADJ
njb-229	168	21	diseases	disease	NOUN
njb-229	168	22	:	:	PUNCT
njb-229	168	23	elsevier	elsevier	NOUN
njb-229	168	24	;	;	PUNCT
njb-229	168	25	2009	2009	NUM
njb-229	168	26	.	.	PUNCT
njb-229	169	1	18	18	NUM
njb-229	169	2	.	.	PUNCT
njb-229	169	3	partridge	partridge	PROPN
njb-229	169	4	sr	sr	PROPN
njb-229	169	5	,	,	PUNCT
njb-229	169	6	kwong	kwong	PROPN
njb-229	169	7	sm	sm	PROPN
njb-229	169	8	,	,	PUNCT
njb-229	169	9	firth	firth	NOUN
njb-229	169	10	n	n	NOUN
njb-229	169	11	,	,	PUNCT
njb-229	169	12	jensen	jensen	PROPN
njb-229	169	13	so	so	ADV
njb-229	169	14	.	.	PUNCT
njb-229	170	1	mobile	mobile	ADJ
njb-229	170	2	genetic	genetic	ADJ
njb-229	170	3	elements	element	NOUN
njb-229	170	4	associated	associate	VERB
njb-229	170	5	with	with	ADP
njb-229	170	6	antimicrobial	antimicrobial	ADJ
njb-229	170	7	resistance	resistance	NOUN
njb-229	170	8	.	.	PUNCT
njb-229	171	1	clinical	clinical	ADJ
njb-229	171	2	microbiology	microbiology	NOUN
njb-229	171	3	reviews	review	NOUN
njb-229	171	4	.	.	PUNCT
njb-229	172	1	2018;31(4):e00088	2018;31(4):e00088	NUM
njb-229	172	2	-	-	SYM
njb-229	172	3	17	17	NUM
njb-229	172	4	19	19	NUM
njb-229	172	5	.	.	PUNCT
njb-229	173	1	european	european	ADJ
njb-229	173	2	centre	centre	PROPN
njb-229	173	3	for	for	ADP
njb-229	173	4	disease	disease	NOUN
njb-229	173	5	pc	pc	PROPN
njb-229	173	6	.	.	PUNCT
njb-229	174	1	surveillance	surveillance	NOUN
njb-229	174	2	of	of	ADP
njb-229	174	3	antimicrobial	antimicrobial	ADJ
njb-229	174	4	resistance	resistance	NOUN
njb-229	174	5	in	in	ADP
njb-229	174	6	europe	europe	PROPN
njb-229	174	7	2016	2016	NUM
njb-229	174	8	.	.	PUNCT
njb-229	175	1	annual	annual	ADJ
njb-229	175	2	report	report	NOUN
njb-229	175	3	of	of	ADP
njb-229	175	4	the	the	DET
njb-229	175	5	european	european	ADJ
njb-229	175	6	antimicrobial	antimicrobial	ADJ
njb-229	175	7	resistance	resistance	NOUN
njb-229	175	8	surveillance	surveillance	NOUN
njb-229	175	9	network	network	NOUN
njb-229	175	10	(	(	PUNCT
njb-229	175	11	ears	ear	NOUN
njb-229	175	12	-	-	PUNCT
njb-229	175	13	net	net	NOUN
njb-229	175	14	)	)	PUNCT
njb-229	175	15	.	.	PUNCT
njb-229	176	1	2017	2017	NUM
njb-229	176	2	.	.	PUNCT
njb-229	177	1	20	20	NUM
njb-229	177	2	.	.	PUNCT
njb-229	177	3	berrazeg	berrazeg	PROPN
njb-229	177	4	m	m	PROPN
njb-229	177	5	,	,	PUNCT
njb-229	177	6	diene	diene	PROPN
njb-229	177	7	sm	sm	PROPN
njb-229	177	8	,	,	PUNCT
njb-229	177	9	drissi	drissi	PROPN
njb-229	177	10	m	m	PROPN
njb-229	177	11	,	,	PUNCT
njb-229	177	12	kempf	kempf	PROPN
njb-229	177	13	m	m	PROPN
njb-229	177	14	,	,	PUNCT
njb-229	177	15	richet	richet	NOUN
njb-229	177	16	h	h	PROPN
njb-229	177	17	,	,	PUNCT
njb-229	177	18	landraud	landraud	PROPN
njb-229	177	19	l	l	PROPN
njb-229	177	20	,	,	PUNCT
njb-229	177	21	et	et	PROPN
njb-229	177	22	al	al	PROPN
njb-229	177	23	.	.	PROPN
njb-229	177	24	biotyping	biotyping	NOUN
njb-229	177	25	of	of	ADP
njb-229	177	26	multidrug	multidrug	NOUN
njb-229	177	27	-	-	PUNCT
njb-229	177	28	resistant	resistant	ADJ
njb-229	177	29	klebsiella	klebsiella	PROPN
njb-229	177	30	pneumoniae	pneumoniae	VERB
njb-229	177	31	clinical	clinical	ADJ
njb-229	177	32	isolates	isolate	NOUN
njb-229	177	33	from	from	ADP
njb-229	177	34	france	france	PROPN
njb-229	177	35	and	and	CCONJ
njb-229	177	36	algeria	algeria	PROPN
njb-229	177	37	using	use	VERB
njb-229	177	38	maldi	maldi	PROPN
njb-229	177	39	-	-	PUNCT
njb-229	177	40	tof	tof	PROPN
njb-229	177	41	ms	ms	PROPN
njb-229	177	42	.	.	PROPN
njb-229	177	43	plos	plos	PROPN
njb-229	177	44	one	one	PROPN
njb-229	177	45	.	.	PUNCT
njb-229	178	1	2013;8(4):e61428	2013;8(4):e61428	NUM
njb-229	178	2	.	.	PUNCT
njb-229	178	3	21	21	NUM
njb-229	178	4	.	.	PUNCT
njb-229	178	5	estabraghi	estabraghi	PROPN
njb-229	178	6	e	e	PROPN
njb-229	178	7	,	,	PUNCT
njb-229	178	8	salehi	salehi	PROPN
njb-229	178	9	tz	tz	PROPN
njb-229	178	10	,	,	PUNCT
njb-229	178	11	aminiq	aminiq	PROPN
njb-229	178	12	k	k	PROPN
njb-229	178	13	,	,	PUNCT
njb-229	178	14	jamshidian	jamshidian	PROPN
njb-229	178	15	m.	m.	PROPN
njb-229	179	1	molecular	molecular	ADJ
njb-229	179	2	identification	identification	NOUN
njb-229	179	3	of	of	ADP
njb-229	179	4	extended	extend	VERB
njb-229	179	5	-	-	PUNCT
njb-229	179	6	spectrum	spectrum	NOUN
njb-229	179	7	β	β	NOUN
njb-229	179	8	-	-	PUNCT
njb-229	179	9	lactamase	lactamase	NOUN
njb-229	179	10	and	and	CCONJ
njb-229	179	11	integron	integron	PROPN
njb-229	179	12	genes	gene	NOUN
njb-229	179	13	in	in	ADP
njb-229	179	14	klebsiella	klebsiella	PROPN
njb-229	179	15	pneumonia	pneumonia	PROPN
njb-229	179	16	.	.	PUNCT
njb-229	180	1	journal	journal	PROPN
njb-229	180	2	of	of	ADP
njb-229	180	3	the	the	DET
njb-229	180	4	nepal	nepal	PROPN
njb-229	180	5	medical	medical	PROPN
njb-229	180	6	association	association	NOUN
njb-229	180	7	.	.	PUNCT
njb-229	181	1	2016;54(202	2016;54(202	NUM
njb-229	181	2	)	)	PUNCT
njb-229	181	3	.	.	PUNCT
njb-229	182	1	22	22	X
njb-229	182	2	.	.	PUNCT
njb-229	183	1	shilpa	shilpa	PROPN
njb-229	183	2	k	k	PROPN
njb-229	183	3	,	,	PUNCT
njb-229	183	4	thomas	thomas	PROPN
njb-229	183	5	r	r	PROPN
njb-229	183	6	,	,	PUNCT
njb-229	183	7	ramyashree	ramyashree	PROPN
njb-229	183	8	a.	a.	NOUN
njb-229	183	9	isolation	isolation	NOUN
njb-229	183	10	and	and	CCONJ
njb-229	183	11	antimicrobial	antimicrobial	ADJ
njb-229	183	12	sensitivity	sensitivity	NOUN
njb-229	183	13	pattern	pattern	NOUN
njb-229	183	14	of	of	ADP
njb-229	183	15	klebsiella	klebsiella	PROPN
njb-229	183	16	pneumoniae	pneumoniae	NOUN
njb-229	183	17	from	from	ADP
njb-229	183	18	sputum	sputum	NOUN
njb-229	183	19	samples	sample	NOUN
njb-229	183	20	in	in	ADP
njb-229	183	21	a	a	DET
njb-229	183	22	tertiary	tertiary	ADJ
njb-229	183	23	care	care	NOUN
njb-229	183	24	hospital	hospital	NOUN
njb-229	183	25	.	.	PUNCT
njb-229	184	1	int	int	PROPN
njb-229	184	2	j	j	PROPN
njb-229	184	3	biomed	biome	VERB
njb-229	184	4	adv	adv	PROPN
njb-229	184	5	res	res	PROPN
njb-229	184	6	.	.	PUNCT
njb-229	185	1	2016;7(2):53	2016;7(2):53	NUM
njb-229	185	2	-	-	SYM
njb-229	185	3	7	7	NUM
njb-229	185	4	.	.	NUM
njb-229	185	5	23	23	NUM
njb-229	185	6	.	.	PUNCT
njb-229	185	7	subedi	subedi	PROPN
njb-229	185	8	s	s	PROPN
njb-229	185	9	,	,	PUNCT
njb-229	185	10	maharjan	maharjan	PROPN
njb-229	185	11	j	j	PROPN
njb-229	185	12	,	,	PUNCT
njb-229	185	13	shrestha	shrestha	PROPN
njb-229	185	14	b.	b.	PROPN
njb-229	185	15	antibiotic	antibiotic	PROPN
njb-229	185	16	susceptibility	susceptibility	NOUN
njb-229	185	17	test	test	NOUN
njb-229	185	18	of	of	ADP
njb-229	185	19	klebsiella	klebsiella	PROPN
njb-229	185	20	pneumoniae	pneumoniae	NOUN
njb-229	185	21	and	and	CCONJ
njb-229	185	22	k.	k.	PROPN
njb-229	185	23	oxytoca	oxytoca	PROPN
njb-229	185	24	isolated	isolate	VERB
njb-229	185	25	from	from	ADP
njb-229	185	26	different	different	ADJ
njb-229	185	27	clinical	clinical	ADJ
njb-229	185	28	samples	sample	NOUN
njb-229	185	29	and	and	CCONJ
njb-229	185	30	perform	perform	VERB
njb-229	185	31	random	random	ADJ
njb-229	185	32	amplified	amplify	VERB
njb-229	185	33	polymorphic	polymorphic	ADJ
njb-229	185	34	dna	dna	NOUN
njb-229	185	35	among	among	ADP
njb-229	185	36	k.	k.	NOUN
njb-229	185	37	pneumoniae	pneumoniae	NOUN
njb-229	185	38	.	.	PUNCT
njb-229	186	1	microbiology	microbiology	NOUN
njb-229	186	2	research	research	NOUN
njb-229	186	3	journal	journal	PROPN
njb-229	186	4	international	international	PROPN
njb-229	186	5	.	.	PUNCT
njb-229	187	1	2016:1	2016:1	NUM
njb-229	187	2	-	-	SYM
njb-229	187	3	11	11	NUM
njb-229	187	4	.	.	NUM
njb-229	187	5	24	24	NUM
njb-229	187	6	.	.	PUNCT
njb-229	188	1	gashe	gashe	PROPN
njb-229	188	2	f	f	PROPN
njb-229	188	3	,	,	PUNCT
njb-229	188	4	mulisa	mulisa	PROPN
njb-229	188	5	e	e	PROPN
njb-229	188	6	,	,	PUNCT
njb-229	188	7	mekonnen	mekonnen	PROPN
njb-229	188	8	m	m	PROPN
njb-229	188	9	,	,	PUNCT
njb-229	188	10	zeleke	zeleke	PROPN
njb-229	188	11	g.	g.	PROPN
njb-229	188	12	antimicrobial	antimicrobial	ADJ
njb-229	188	13	resistance	resistance	NOUN
njb-229	188	14	profile	profile	NOUN
njb-229	188	15	of	of	ADP
njb-229	188	16	different	different	ADJ
njb-229	188	17	clinical	clinical	ADJ
njb-229	188	18	isolates	isolate	NOUN
njb-229	188	19	against	against	ADP
njb-229	188	20	thirdgeneration	thirdgeneration	NOUN
njb-229	188	21	cephalosporins	cephalosporin	NOUN
njb-229	188	22	.	.	PUNCT
njb-229	188	23	journal	journal	PROPN
njb-229	188	24	of	of	ADP
njb-229	188	25	pharmaceutics	pharmaceutic	NOUN
njb-229	188	26	.	.	PUNCT
njb-229	189	1	2018;2018	2018;2018	NUM
njb-229	189	2	25	25	NUM
njb-229	189	3	.	.	PUNCT
njb-229	190	1	parajuli	parajuli	PROPN
njb-229	190	2	np	np	PROPN
njb-229	190	3	,	,	PUNCT
njb-229	190	4	acharya	acharya	PROPN
njb-229	190	5	sp	sp	PROPN
njb-229	190	6	,	,	PUNCT
njb-229	190	7	mishra	mishra	PROPN
njb-229	190	8	sk	sk	PROPN
njb-229	190	9	,	,	PUNCT
njb-229	190	10	parajuli	parajuli	PROPN
njb-229	190	11	k	k	PROPN
njb-229	190	12	,	,	PUNCT
njb-229	190	13	rijal	rijal	PROPN
njb-229	190	14	bp	bp	PROPN
njb-229	190	15	,	,	PUNCT
njb-229	190	16	pokhrel	pokhrel	PROPN
njb-229	190	17	bm	bm	PROPN
njb-229	190	18	.	.	PUNCT
njb-229	191	1	high	high	ADJ
njb-229	191	2	burden	burden	NOUN
njb-229	191	3	of	of	ADP
njb-229	191	4	antimicrobial	antimicrobial	ADJ
njb-229	191	5	resistance	resistance	NOUN
njb-229	191	6	among	among	ADP
njb-229	191	7	gram	gram	NOUN
njb-229	191	8	negative	negative	ADJ
njb-229	191	9	bacteria	bacteria	NOUN
njb-229	191	10	causing	cause	VERB
njb-229	191	11	healthcare	healthcare	NOUN
njb-229	191	12	associated	associate	VERB
njb-229	191	13	infections	infection	NOUN
njb-229	191	14	in	in	ADP
njb-229	191	15	a	a	DET
njb-229	191	16	critical	critical	ADJ
njb-229	191	17	care	care	NOUN
njb-229	191	18	unit	unit	NOUN
njb-229	191	19	of	of	ADP
njb-229	191	20	nepal	nepal	PROPN
njb-229	191	21	.	.	PUNCT
njb-229	192	1	antimicrobial	antimicrobial	ADJ
njb-229	192	2	resistance	resistance	NOUN
njb-229	192	3	&	&	CCONJ
njb-229	192	4	infection	infection	NOUN
njb-229	192	5	control	control	NOUN
njb-229	192	6	.	.	PUNCT
njb-229	193	1	2017;6(1):67	2017;6(1):67	NUM
njb-229	193	2	26	26	NUM
njb-229	193	3	.	.	PUNCT
njb-229	194	1	paterson	paterson	PROPN
njb-229	194	2	dl	dl	PROPN
njb-229	194	3	.	.	PROPN
njb-229	194	4	recommendation	recommendation	NOUN
njb-229	194	5	for	for	ADP
njb-229	194	6	treatment	treatment	NOUN
njb-229	194	7	of	of	ADP
njb-229	194	8	severe	severe	ADJ
njb-229	194	9	infections	infection	NOUN
njb-229	194	10	caused	cause	VERB
njb-229	194	11	by	by	ADP
njb-229	194	12	enterobacteriaceae	enterobacteriaceae	PROPN
njb-229	194	13	producing	produce	VERB
njb-229	194	14	extended	extend	VERB
njb-229	194	15	-	-	PUNCT
njb-229	194	16	spectrum	spectrum	NOUN
njb-229	194	17	βlactamases	βlactamase	NOUN
njb-229	194	18	(	(	PUNCT
njb-229	194	19	esbls	esbls	PROPN
njb-229	194	20	)	)	PUNCT
njb-229	194	21	.	.	PUNCT
njb-229	195	1	clinical	clinical	ADJ
njb-229	195	2	microbiology	microbiology	NOUN
njb-229	195	3	and	and	CCONJ
njb-229	195	4	infection	infection	NOUN
njb-229	195	5	.	.	PUNCT
njb-229	196	1	2000;6(9):460	2000;6(9):460	NUM
njb-229	196	2	-	-	SYM
njb-229	196	3	3	3	NUM
njb-229	196	4	.	.	NUM
njb-229	196	5	27	27	NUM
njb-229	196	6	.	.	PUNCT
njb-229	197	1	miller	miller	PROPN
njb-229	197	2	s	s	PROPN
njb-229	197	3	,	,	PUNCT
njb-229	197	4	humphries	humphries	PROPN
njb-229	197	5	rm	rm	PROPN
njb-229	197	6	.	.	PUNCT
njb-229	198	1	clinical	clinical	ADJ
njb-229	198	2	laboratory	laboratory	NOUN
njb-229	198	3	detection	detection	NOUN
njb-229	198	4	of	of	ADP
njb-229	198	5	carbapenem	carbapenem	NOUN
njb-229	198	6	-	-	PUNCT
njb-229	198	7	resistant	resistant	ADJ
njb-229	198	8	and	and	CCONJ
njb-229	198	9	carbapenemase	carbapenemase	NOUN
njb-229	198	10	-	-	PUNCT
njb-229	198	11	producing	produce	VERB
njb-229	198	12	enterobacteriaceae	enterobacteriaceae	PROPN
njb-229	198	13	.	.	PUNCT
njb-229	199	1	expert	expert	NOUN
njb-229	199	2	review	review	NOUN
njb-229	199	3	of	of	ADP
njb-229	199	4	anti	anti	ADJ
njb-229	199	5	-	-	ADJ
njb-229	199	6	infective	infective	ADJ
njb-229	199	7	therapy	therapy	NOUN
njb-229	199	8	.	.	PUNCT
njb-229	200	1	2016;14(8):705	2016;14(8):705	NUM
njb-229	200	2	-	-	SYM
njb-229	200	3	17	17	NUM
njb-229	200	4	http://atlas.ecdc.europa.eu/public/index.aspx?instance	http://atlas.ecdc.europa.eu/public/index.aspx?instance	NOUN